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Maintenance of vascular homeostasis requires a coordinated and regulated response 
by endothelial cells. ECs form the inner lining of blood and lymphatic vessels and form 
an interface between the luminal vessel fluid and surrounding tissue. They are hence 
involved in a large number of physiological processes and implicated in many 
pathologies. The fundamental biology of ECs must therefore be studied in order to 
understand the role of ECs in normal physiology and disease. My lab focusses on 
research into ECs and in the generation of in vitro EC culture models to explore its roles 
in angiogenesis. I aimed to analyse EC growth and proliferation under different 
conditions. An additional aim was to optimise a tumour angiogenesis co-culture assay, 
which analyses the growth of blood vessels towards tumour spheroids. Finally, I set out 
to study the surface polarity of a number of important cell surface proteins in human 
umbilical vein endothelial cells by means of surface protein labelling and analysis. A 
variety of in vitro assays were used across this work, including that for cell proliferation, 
tube formation and protein identification.  
       Optimal HUVEC culture conditions were analysed and determined. HUVEC grow 
and proliferate greatest in Lonza EGM-2 media, however ECs from transgenic 
fluorescent zebrafish larvae require alternate cell culture conditions. HUVEC also have 
varying growth abilities on different surfaces, with a nanostructured surface generating 
low confluency of cells which also developed markers of genetic instability. Optimisation 
of HUVEC culture conditions led to investigation of their capacity to form vascular 
tubules in a co-culture with normal human dermal fibroblasts. An optimal vascular 
density to effectively determine vascular directionality towards tumour spheroids was 
achieved, with future prospects to assess the angiogenic effects of growth factors and 
drugs in culture. Failure to develop a novel method to label HUVEC surface proteins for 
proteomic analysis revealed that further work on this needs to be carried out, however 
immunofluorescence has shown to be a valid, low-throughput method to label and 
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Chapter 1 - Introduction  
 
1.1 Endothelial cells 
ECs are the cobblestone-like cells that line blood vessels and form the barrier between 
the blood supply and the surrounding tissue [1] [2]. Their apical surface is in direct 
contact with components of the blood system, while their basal surface is sat on the 
basal lamina – a specialised extracellular matrix (ECM) on which ECs lie. They are 
tightly packed together into a monolayer [3] of squamous epithelial-like cells, generally 
forming a continuum along blood vessels and the lymphatics (Figure 1.1). Nearly every 
tissue requires a blood supply and so ECs are exploited in large amounts, performing 
many functions required of a circulatory system. There is no doubt, then, that these cells 
form one of the largest organ systems in the animal body. The average human has 
around 1kg of ECs [4], a considerable mass since these cells are some of the thinnest 
in the body and only compose of a single sheet inside the circulatory system.  
 
 
1.1.1– Endothelial cell structure  
ECs are extremely thin cells relative to other cells in the body, at about 0.1-1 µm thick 
[5]. They have a diameter of roughly 10-100x this, generating flat, polygonal cells that 
are tightly packed to reflect their key function – to allow the selective passage of 
nutrients and metabolites through them [4]. The organisation and array of sub-cellular 
organelles within ECs is relatively simple. Organelles, including the endoplasmic 
reticulum and Golgi apparatus, are mostly situated around the nucleus and ECs also 
include a relatively larger concentration of pinocytic vesicles [5]. These are vesicles that 
are involved in the bulk transport of molecules from the extracellular space across the 
membrane by means of membrane invagination. ECs are unique in that they are the 
only cell type to contain Weibel-Palade bodies [6]. These are tubular organelles whose 
formation is driven by the constituent they secrete; von Willebrand factor (vWF) [6].  
vWF has a vital role in haemostasis whereby it activates and subsequently adheres 
platelets to the endothelial lining to form a temporary blood clot as a prerequisite to 
thrombosis [7].  
 
1.2 – Vessel composition  
The role of vessels, in general, is to transfer fluid and fluid solute from one area of the 
body to another. Each type of vessel has a distinct function which is reflected in its 
































Figure 1.1 – Endothelial cells form the lining of all blood vessels. In Arteries (left) 
and veins (right), ECs form the lining of the blood vessel, separating the lumen of the 
vessel from the surrounding tissue. Smooth muscle cells form exterior to the 
endothelium which are then surrounded by connective tissue. Original image created 















monolayer of ECs [2] surrounded by an associated layer of connective tissue, called the 
basal lamina [8]. Both blood and lymphatic capillaries consist only of this single layer 
and associated basal lamina. In contrast, all the other vessel types contain additional 
layers of connective tissue, elastic fibres and smooth muscle cells (SMCs) [8] (Figure 
1.2). A tight, coherent sheet of ECs is common to most vessels, maintained by high 
affinity interactions between intercellular monogenic cell adhesion molecules such as 
vascular endothelial cadherin (VE-cadherin) [9]. However, in the blood and lymphatic 
system, the capillary vessels are discontinuous [10]. They have intercellular clefts 
between their cell-cell junctions which allows for the passage of plasma proteins [11]. 
 
1.2.1– The circulatory system 
As previously stated, different types of vasculature have distinct functions and hence 
their cellular compositions differ depending on their physiological role [8]. The blood 
system forms a continuous, closed circuit of hollow tubes around the body. It acts as a 
conduit for blood, which is pumped from the heart to every tissue in the body. Arteries 
carry blood away from the heart and generally carry oxygenated blood (Figure 1.2). 
They are all branches from the main artery, the aorta, with the exception of the 
pulmonary artery. The pulmonary artery differs from the rest of the body’s arteries as it 
carries de-oxygenated blood. Blood is pumped at relatively high pressure out of the left 
ventricle of the heart though the aorta to all parts of the body [4]. The volume of tissue 
that needs to receive this oxygen rich blood is high, and so the heart must ensure a high 
pressure is maintained throughout the entirety of the arterial vessels. It does this by 
ventricular contraction, which traverses throughout the arteries. The pressure is relieved 
during ventricular relaxation. Arteries must have the capacity to withstand high pressure 
during systole and low pressure during diastole [4]. Arteries therefore must have thick 
walls with large amounts of elastic tissue to allow for stretch and recoil. Arteries have an 
endothelium sat on a basement membrane (tunica intima) that is surrounded by a thick 
layer of SMCs. These SMCs are sandwiched between two layers of elastic fibres (tunica 
media). The outer most layer is composed of connective tissue, called tunica externa 
(Figure 1.3). Their highly elastic properties, along with their large radii, allows for low 
resistance transport of blood around the body [11]. Low resistance in arteries is 
desirable to allow oxygenated blood to reach far reaching tissues. 
       The finest branches of the arterial tree are arterioles [11]. These carry oxygenated 
blood from arteries and pass it onto capillaries (Figure 1.2). Capillaries are 
phenotypically diverse, however in general they are composed of just a single cell layer 
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of ECs, along with a small amount of basal lamina and a few scattered pericytes [4,12] 
(Figure 1.3). Pericytes wrap themselves around the vessel and perform a variety of 
functions, mostly involving contraction of the vessel to regulate blood flow and vessel 
permeability [13,14]. The role of capillaries is to permeate extensive microscopic 
branches into tissues so that every cell in the body is around 100µm away from a 
capillary vessel [15]. This close proximity allows for the passage of oxygen and other 
nutrients across the endothelial lining and into the surrounding stroma before entering 
parenchymal tissue. Due to their thin vessel wall, blood pressure here must be lower to 
not rupture the capillary wall. Hence, arterioles are the major site of vascular resistance 
since they sit upstream of capillaries [11]. Arterioles, like arteries, have a characteristic 
tri-layer of vessel components; an intima of ECs sat on a basement membrane, a media 
layer of elastic fibres and SMCs, with collagen bundles, nerve endings and fibroblasts 
composing of the tunica externa layer [5] (Figure 1.3). These three layers interact in 
such a way that the radii of arterioles have plasticity. This allows for regulation of mean 
arterial pressure. Vasodilation of arterioles will increase the volume of the arteriole 
vessels and allow more blood to pass through them, at a lower pressure. Blood moves 
more slowly and hence has a longer time to passage solutes through the endothelium 
and into the surrounding tissue. This response is required during periods of exercise. 
Vasoconstriction of the SMCs will increase blood pressure due to lowering the radii of 
the arterioles. This flow resistance is altered via external signals such as metabolic 
factors, which affect the baseline level of contraction of SMC, known as the intrinsic 
tone [16]. These signals work by altering the Ca2+ within the cytoplasm of the SMCs and 
thus affecting the motion of their intrinsic myosin motor proteins and length of the actin 
microfilaments.  
       After its route through the capillary network, the blood will now be de-oxygenated as 
it has unloaded all its oxygen and nutrients to tissues on its route around the body. 
Here, it is collected into venules (Figure 1.2). These are microscopic vessels with the 
same cellular composition as arterioles however they have a much thinner layer of SMC 
[17]. The blood pressure here is very low and so additional valves and skeletal muscle 
contractions are needed to pump the blood to the veins.  
     Veins collect the de-oxygenated blood from the venules and take it back to the heart 
via the vena cava, the body’s main vein [11]. The pressure difference between the veins 
and the right atrium, where the blood enters the heart from the venous system, is the 
driving force for venous return. The pressure is lower in the right atrium than in the veins  
and hence this gives the blood a potential energy to drive movement [11]. There needs 
to be very low resistance within the vessel to allow blood to easily flow to the heart. 
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Their vessel walls are therefore thinner and much more submissive than those of 
arteries and arterioles. They, too, are composed of an endothelial lining surrounded by 
elastic layers, smooth muscle layer and connective tissue however all these layers are 
comparatively thinner to allow for a wider lumen [11]. Once in the right atrium it passes 
through a tricuspid valve and is pumped into the right ventricle. It is now pumped to the 
lungs via the pulmonary artery to be re-oxygenated. Composing of a double circulatory 
system, the blood, having picked up oxygen at the lungs, is looped back to the left 
atrium at the heart via the pulmonary vein. This is the only vein that passages 
oxygenated blood. This blood is pumped into the left ventricle, where it is then forced 
out during ventricular systole.  
 
1.2.2 – The lymphatic system 
The lymphatic system is a unidirectional fluid transport system, similar to the circulatory 
system but carrying lymph fluid rather than blood. It is intimately linked to the circulatory 
and immune system [11], working in coordination with these two systems independently 
to achieve whole body homeostasis. It comprises a vascular tree, termed lymphatics, 
carrying lymph that has been absorbed from tissues and returns it to the circulatory 
system. The lymphatic system has three main purposes. Firstly, it balances fluid 
retention in tissues by absorbing excess interstitial fluid that has not been able to pass 
into the circulatory system across the capillary wall [11]. Secondly, it acts as a filter for 
the interstitial fluid that is absorbed from tissues. The lymph nodes, lymphatic organs 
connected to lymphatic vessels, contain immune cells, which are activated upon 
recognition of any pathogens present fluid passed through them. These immune cells 
have the capacity to secrete antibodies specific for that pathogen, which are passaged 
along the lymphatic vessels to the circulatory system and into tissues to help fight an 
infection [18]. The other function of the lymphatic system is to absorb fats from the small 
intestine [11].  
       Afferent lymph is collected by small lymphatic capillaries from interstitial spaces 
around cells in the body [18]. The capillary vessels merge and are collected in ducts, 
which lead onto afferent lymph trunks. These are akin to veins of the circulatory system 
[11]. Lymphatic trunks act as conduits, directing lymph flow towards lymph nodes, away 
from blood capillaries. The lymph passes through the lymph nodes and is filtered for 
pathogens.  After passing through the lymph nodes, the lymph is now termed efferent 
lymph, and is drained back into the circulation through the subclavian veins via the 








































Figure 1.2 – Organisational hierarchy of the blood vasculature. Oxygenated blood 
flows away from the heart in arteries, the largest vessel type carrying oxygenated 
blood. Smaller vessels which branch away from these arteries are arterioles. These 
carry blood into tissues via capillaries, the smallest branches of the arterial tree. Blood 
here becomes deoxygenated as it diffuses into cells within tissues, and this blood 
emerges in venules. These are the most finite branches of the venous tree and adjoin 
to venules. These carry blood to the main branches, veins, which carry the blood 









































Figure 1.3 – Vessel composition of the blood vasculature. a) Larger vessels i.e. the 
arteries and veins, have multiple layers of elastic tissue separating the endothelium and 
its basal lamina from SMCs and the outer layer of fibrous tissue. This gives structural 
support and ability to contract and recoil. Smaller branches of these, the arterioles and 
venules, have the same trilaminar structure however these layers are relatively thinner. 
b) Capillaries have minimal layering outside of the EC and basal laminal layer, 
composing of some SMCs and pericytes. Images adapted from (a) medical gallery of 




       Lymphatic capillaries are analogous to continuous blood capillaries in that they are 
simply a monolayer of non-fenestrated ECs; however, they have a surrounding 
discontinuous basal lamina. Because of their thinness and connective tissue 
discontinuity, they have additional anchoring filaments within the vessel to prevent 
collapse [11]. These present parallel to the longitudinal axis of the lymphatic capillary 
wall and extend into the surrounding connective tissue. They offer the binding 
mechanism responsible for joining the lymphatic capillary wall to the connective tissue.  
Lymph vessels differ from blood capillaries in that they are blind at their distal end and 
the ECs overlap slightly [11,18]. The gaps perpendicular to the two overlapping ECs 
allows interstitial fluid to enter the conduit, which can only pass in one direction due to 
the closed distal end [18]. The capillaries join to collecting vessels, also known as 
trunks, via pre-collecting vessels. These pre-collecting vessels contain bicuspid valves 
at irregular intervals, differing from trunks which have similar valves at regularly spaced 
intervals [18]. This is due to pre-collecting vessels having a discontinuous EC lining, 
allowing interstitial fluid to enter the vessel. However, they differ from capillary 
lymphatics as they have SMC in their vessel wall to allow for propulsion of lymph 
forward [19]. This makes them functionally distinct from both capillary lymphatics and 
collecting lymphatics in that they both absorb fluids and propel it forwards. Trunks have 
a continuous EC lining and basal lamina, as well as a layer of smooth muscle cells and 
collagen fibres. They also contain regular spaced bicuspid valves to maintain the 
unidirectionality of the fluid flow [18]. Their walls are alike to that of blood vessels in that 
they are surrounded by one or more layers of SMC, capable of contracting to push the 
fluid in the anterograde direction, and collagen fibres [19]. The unit of vessel separating 
two bicuspid valves is called a lymphangion (Figure 1.5). 
 
1.2.2.1 Lymphatic organs 
The circulatory system is comprised of vessels, luminal fluid and an organ – the heart. 
So too does the lymphatics system. Here, lymphatic organs are classified as either 
primary or secondary organs [19]. The function of primary lymphoid organs is to 
generate lymphocytes and to allow for their maturation [18]. These organs include the 
bone marrow and the thymus. The role of the secondary tissue is for further maturation 
of these lymphocytes and to initiate a secondary immune response via B cell and T cell 
activation. The constituents of this secondary immune response include the spleen and 



























       
Figure 1.4 - The lymphatic system. Interstitial fluid from blood micro-vessels enters 
lymphatic capillaries to become lymph. This is pumped along afferent lymphatic vessels 
and converge at lymphatic trunks, also called collecting vessels. The lymph is directed 
towards lymph nodes, where it is screened for pathogens. An adaptive immune 
response ensues if pathogens are detected, and the lymph is passaged back into blood 
circulation via efferent lymphatic vessels leading to lymphatic ducts and the subclavian 




Figure 1.5 – A lymphangion. A contractile unit to propel lymph through lymphatic 
trunks towards lymph nodes. At either end of the lymphangion are bicuspid valves; these 
only open in one direction to maintain unidirectionality of lymph towards the lymph nodes 
and prevents backflow. Outside of the EC monolayer and basal lamina is a layer of SMC 
and collagen fibres that promote contraction of the unit. Image taken from K. N. Margaris 




















1.3 – Endothelial cell lineage        
The endothelium is the first organ system to be developed in embryogenesis. 
Embryogenesis begins with a fertilised egg, the zygote. This zygote is thought of as 
totipotent [20]; it is a stem cell capable of replicating indefinitely and differentiating into 
any cell type in the adult human body. This embryonic tissue will go on to form the 
entirety of tissue in the adult body. As the zygote divides, its constituent cells begin to 
differentiate [20]. The cells facing the external environment express more epithelial 
characteristics and become the ectoderm germ cell line. Cells in the centre of the mass 
of cells forms the endoderm germ cell line, forming the gastro-intestinal tract and its 
appendages. Mesodermal cells, EC precursors [2], fill the space in between these two 
other germ line cells. This mesodermal embryonic tissue will go on to develop many 
internal organs such as the vascular system, skeleton, muscle and connective tissue [2].  
       On their route to becoming fully matured and specialised ECs, the mesodermal 
stem cells first differentiate into hemangioblasts at the primitive streak. The primitive 
streak defines the point at which all three germ cell lines are formed. These 
hemangioblasts have the potential to form both hematopoietic stem cells (HSCs) and 
EC precursor cells, angioblasts, respectively (Figure 1.6). To form ECs, the 
hemangioblasts are stimulated differently than when forming HSCs. These two stem cell 
lines are multipotent and can only go on to generate blood cells and ECs respectively 
[21]. The presence of this hemangioblast cell line was discovered nearly a century ago 
[21] as scientists discovered a simultaneous formation of HSCs and angioblasts at the 
primitive streak. This coupling was also observed in the equivalent structure in 
zebrafish, giving further justification to the presence of a common progenitor.  
       The molecular players involved in the specialisation of mesodermal stem cells into 
hemangioblasts and then into ECs has since been discovered. A number of growth 
factors and transcription factors have been identified which promote this differentiation. 
It seems FGF acts as the ‘time director’ [21], controlling the expression of other growth 
factors involved in hemangioblast formation. In addition, Runx1 is a transcription factor 
that acts as a master regulator, binding to DNA promotor regions and upregulating the 
expression of further hematopoietic transcription factors [21]. These transcription factors 
are themselves involved in the programming of the cell towards haematopoiesis, for 
instance upregulating genes for growth factor receptors. VEGF acts as a growth factor 
that directly influences the development of hemangioblasts. It binds to VEGF receptors 
present on the surface of mesodermal cells, inducing an intracellular signalling cascade 
and promoting the differentiation of mesodermal cells into hemangioblasts. Other 
players that directly promote this cellular differentiation are BMP4 and ZBP-89[21][12] 
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(Figure 1.6).  
       The fate of these hemangioblasts is decided via the Renin-angiotensin system. It 
acts as a switch in directing the differentiation of the hemangioblast either towards HSC 
or angioblasts. Angiotensin II type 1 binding to its receptor on hemangioblasts directs 
cell fate towards angioblasts, forming the different EC types. Conversely, Angiotensin II 
type 2 binding to its receptor directs hemangioblasts towards hematopoietic lineages 
[21]. Both cell lines are utilised during early development and in adult life, and so the 
relative progression down each pathway depends on the balance of molecular players 
of the renin-angiotensin system acting on each. If a cell reaches the angioblast stage, it 
has a decision whether to form one of three EC types. These different EC types fall 
within two different specialized vascular systems. These systems compose of blood 
vessels and lymphatic vasculature. These two systems have distinct functions and so 
their cellular composition must reflect this [21]; ECs in both systems are specialised. 
Lymphatic ECs (lECs) form the inner most layer of the lymphatic system, while venous 
ECs (vECs) and arterial ECs (aECs) provide the division between the blood and outer 
vessel layers in the blood vasculature.  
       The first and default status of ECs in vasculature development is vEC formation 
[12,21]. This EC status is maintained by low Notch signalling, achieved by the inhibition 
of arterial specific genes, including Notch. (Figure 1.6). In contrast, high Notch 
signalling, and therefore removal of Notch inhibition [22], upregulates aEC formation, 
diverging EC development away from vEC. Shh and VEGF signalling act upstream of 
Notch [22], upregulating its expression and hence maintaining a high amount of it in the 
developing organism. The final type of EC forms the inner lining of the entire lymphatic 
system; lECs. To direct angioblasts to lECs, Prox1, Sox18, Syk and SLP-76 are 
upregulated [22]. These ECs go on to form a distinct circulatory system that is mostly 
disconnected to the blood vasculature.  
 
1.4 - Formation of vasculature during development 
Vasculature development during embryogenesis involves three processes; 
vasculogenesis, angiogenesis and Lymphangiogenesis. Lymphangiogenesis provides 
all vascular routes for lymph to flow [23]. Angiogenesis and vasculogenesis, however, 
account for blood vasculature formation. Blood vasculature carries blood and its solutes, 
and these two formulative processes are clearly distinct from one another. Major break-





















Figure 1.6 - Derivation of the different types of endothelial cells involved in 
vasculature development. Embryonic stem cells differentiate into the three germ line 
cells, of which the mesoderm cells go on to differentiate and form many of the internal 
organs of the body. Mesodermal stem cells are formed in the bone marrow, and then 
go on to specialise into hemangioblasts after mitogen stimulation. The fate of the 
hemangioblasts is decided by the renin-angiotensin system, which acts as a switch 
between HSC and angioblast generation. vECs are the default angioblast derived EC 
type, generated via relatively low Notch signalling. In contrast, high Notch signalling is 
maintained in angioblasts to become aECs. Shh and VEGF signalling promote 
angioblast differentiation into aECs by upregulating Notch signalling. Prox1 and Sox18 
are upregulated during lymphatics development to generate vessels with lEC lined 
lumens. Syk tyrosine kinase and its adaptor, SLP-76, are the main players that 



























 mostly brought about by studies carried out on ‘knock-out’ mice [9]. Vasculogenesis 
occurs developmentally prior to angiogenesis and is the de novo formation of blood 
vessels in an area previously devoid of vasculature [24]. It is driven by the aggregation 
of undifferentiated mesodermal cells, which then differentiate into ECs and form 
elongated tubes. Angiogenesis occurs after vasculogenesis begins, as it is the formation 
of blood vessels from existing vasculature. Its driving force is the proliferation and 
migration of ECs, forming elongated tubes [24], directed by a tip EC that has different 
characteristics to its follower cells. Lymphatic development has characteristics that 
overlap with vasculogenesis and angiogenesis; selected cells upregulate genes 
involved in ‘budding’ away from the source of lECs, directed by a mitotic stimulus 
towards mesenchymal tissue. In all cases of vessel formation, angioblasts are the 
precursor cells responsible for providing the entire populations of blood vessel ECs. 
These angioblasts will specialise into the three different types of EC, which undergo 
separate but distinct processes of development into tubules [25]. 
 
1.4.1 - Vasculogenesis 
Vasculogenesis is the de novo formation of blood vessels and occurs during early 
embryonic development as well as in the adult [25]. The process of vasculogenesis 
begins with progenitor cells as described previously. Mesoderm germ cells cluster into 
aggregates called blood islands, embryonic versions of bone marrow [24], at the 
primitive streak at day 17 in humans [26]. After receiving secretory factors from the 
underlying endoderm [27], some of the mesodermal germ cells then segregate into 
hemangioblastic aggregates. Remaining undifferentiated, mesodermal cells then 
surround these aggregates, flattening against the core. The hemangioblastic core will 
then differentiate into primitive blood cells. The encapsulating undifferentiated 
mesodermal cells will differentiate into hemangioblasts and then angioblasts. In a 
secondary phase of vasculogenesis these angioblasts will become ECs during further 
differentiation, which are still surrounding the HSC aggregate [28]. This forms a 
spherical capillary. The third stage involves these ECs migrating and converging, fusing 
to form the 3D primary capillary plexus, the initial capillary network in the embryo. 
During fusion of the cellular plasma membranes, a hollow network emerges with a fluid 
filled lumen. This system continues to expand during embryogenesis by means of 
vasculogenesis, and angiogenesis [26]; the sprouting of new vessels from existing 
capillary vessels. Vessels formed by vasculogenesis will have no SMC layer, or 
associated pericyes and remains as a simple sheet of ECs for a considerable amount of 
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time before they form mature vessels [24].    
     During embryogenesis, vasculogenesis occurs in two distinct and independent sites. 
The primary site of vasculogenesis occurs in extraembryonic regions (Figure 1.7a). 
Hemangioblasts within the wall of the yolk sac, an extraembryonic membranous sac 
lined with endoderm with surrounding mesenchymal cells and derived from the 
mesoderm, give rise to blood island aggregates. The centre of these blood islands 
differentiates into blood cells and the exterior of the islands form ECs, which form the 
vasculature of the early embryo necessary to transport nutrients and metabolites 
between mother and embryo [28]. The secondary site of vasculogenesis occurs intra-
embryonically (Figure 1.7b). Undifferentiated mesoderm germ cells from within the 
organs of the embryo differentiate into ECs after forming a hollow sphere, which form 
capillary networks via tubular fusing across the entire body. Hemangioblastic 
aggregates do not congress in the centre of these ECs. 
       Capillary fusing during vasculogenesis occurs in two mechanisms [28]. One process 
of lumen formation involves the intracellular vesicle fusion after ECs aggregation. These 
fused vesicles will then fuse with the plasma membrane at the point of cellular contact, 
forming a fluid filled lumen whose membrane is composed of plasma membranes from 
all cells in the cluster [28]. Another method involves the formation of intracellular lumina, 
formed from endocytosis of the plasma membrane, within each individual cell. The 
coalesced vesicles can then form a channel within the cell, and fusion with the tip of 
each cell will form a continuous lumen throughout the cells in contact with one another 
[28].  
 
1.4.2 – Angiogenesis 
Angiogenesis is a process that involves the growth of blood vessels from existing 
vasculature. Angiogenesis relies on the presence of existing ECs and hence provides a 
faster route to blood vessel formation than its partner process, vasculogenesis. It is 
heavily exploited during embryogenesis where vasculature must develop rapidly for 
nutrients to deliver to developing tissue, however there must be an initial stage of 
vasculogenesis to gain a vasculative foothold. Angiogenesis is the main process for 
vasculature maintenance, and its activity responds to the metabolic activity of the 
organism [20]. Energy supply to tissues must be equal to energy demand to reach a 
state of metabolic homeostasis. When the body’s demands for nutrients and other 
components of the blood increases, such as when the body’s mass increases, the 













Figure 1.7 – Vasculogenesis. (a) Extraembryonic vasculogenesis begins in the 
wall of the yolk sac. Mesenchymal germ cells specialise into blood cell precursor 
cells, which cluster into blood islands. The cells on the aggregate exterior 
differentiate into endothelial precursor cells, whilst those cells in the core go on to 
form primitive blood cells. The EC cells proliferate and migrate, forming a capillary 
plexus. (b) Intraembryonic vasculogenesis involves a similar aggregation of 
mesodermal precursor cells but these all specialise into hollow tubes of ECs, with 






metabolic activity, angiogenesis declines and so, too, does vascular density. This 
association between vascular density and metabolism is relevant to both health and 
disease. 
       The angiogenic activity of an organism depends on the balance of different 
secreted factors released from regions of tissue lacking in sufficient blood supply. Pro-
angiogenic molecules will shift the balance in the favour of angiogenesis, whereas anti-
angiogenic molecules will do the opposite. The major player in the up-regulation of 
angiogenesis is vascular endothelial growth factor-A (VEGF-A) [29]. Most frequently it is 
hypoxia that is the trigger for parenchymal cells, the functional cells of a tissue, to 
release VEGF-A  [30]. VEGFs are potent soluble pro-angiogenic factors that act on ECs 
to induce an intracellular signalling response. As a result of this response, ECs migrate 
and align with the VEGF concentration gradient, which coordinates angiogenesis. 
 
1.4.2.1 - Angiogenic factors  
VEGF encompasses a seven-part family of molecules, each with a common VEGF 
homology domain [31]. This core has a cysteine knot motif, the cysteine residues 
contributing to intra- and intermolecular di-sulphide bonds that occur at one end of the 
four-stranded β-sheet VEGF monomer [31]. This dimerizes with another monomer to 
form an anti-parallel dimer [31]. The dimeric VEGF binds to one of three VEGF 
receptors (VEGFRs) present on ECs. VEGF-A is the best characterised member of the 
VEGF family. It can undergo alternate splicing to generate four alternate molecules [32], 
which can bind to heparan sulphate proteoglycans (HPSGs) in the ECM. These 
molecules have differing numbers of amino acids present after the signal sequence is 
cleaved from the main body. VEGF189 and VEGF206 bind to HPSGs via heparin-binding 
surfaces with high affinity [32]. Conversely, VEGF121 lacks this heparin binding surface 
and hence cannot bind to HPSGs in the ECM. VEGF165 has a heparin-binding surface 
but its affinity is not as high as VEGF189 and VEGF206.  
       Epidermal growth factor (EGF) and Transforming growth factor α (TGF-α) are also 
soluble pro-angiogenic factors. They act to induce proliferation of ECs and have shown 
to increase angiogenesis in vivo [33]. Both these molecules bind to the EGF receptor to 
induce a signalling response. This signalling response in a cancer cell has been shown 
to induce cell proliferation, angiogenesis and metastasis [33] giving a similar response to 
VEGF in these cells.   
       Anti-angiogenic factors are less well characterised than pro-angiogenic players. 
They are expressed in normal physiology to prevent excess blood vessel formation, 
which would be energy costly and unnecessary, and potentially tumourigenic. 
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Endostatin is a globular protein derived from collagen [34], found naturally in the body. It 
interferes with the cell cycle; disrupting intracellular signalling cascades resulting in cell 
cycle arrest and apoptosis [34]. Other factors which act in a similar manner are also 
fragments of naturally occurring physiological components. Angiostatin is a fragment of 
plasminogen, a pro-enzyme responsible for degrading inappropriate or old fibrin clots 
[35]. It is constitutively secreted by the liver in an inactive form [35], which activates on 
interaction with a fibrin clot. Both collagen and plasminogen are present in constant 
amounts in the body in normal physiology and so amounts of both the anti-angiogenic 
factors will be relatively constant. This maintains the balance between the pro- and anti-
angiogenic states; angiogenesis only being upregulated when the balance of factors 
spills more towards the pro-angiogenic side. 
 
1.4.2.2 - VEGF Receptors   
VEGFRs are tyrosine kinases, each with seven immunoglobulin-like domains present in 
the extracellular region and a single pass transmembrane domain separating the 
extracellular region from the intracellular kinase domain [36]. Tyrosine kinases, on 
binding their substrate, hetero or homodimerize leading to the autophosphorylation of 
their C-terminus and the initiation of an intracellular signalling cascade. VEGFR-1 and 
VEGFR-2 are the predominate VEGFRs present on vascular ECs [31] and so are the 
most important VEGFRs in angiogenesis in later stages of an organism’s development. 
Their molecular weights are 180 kDa and 210 kDa respectively. VEGFR-3 is expressed 
on vECs during embryonic development [31] and so is important for neovascularisation 
in early development. VEGFR-1 and VEGFR-2 are upregulated in tumour cells, as is 
VEGF [37]. VEGFR-2 interaction with VEGF is thought to be the main driving force for 
angiogenesis. Recent findings have suggested that VEGFR-1 and -2 are present in 
different amounts at the apical and basal surface of neural microvascular endothelial 
cells (MVECs) [38]. VEGFR1 having a greater distribution at the apical surface, and 
VEGFR2 present in greater amounts at the basal surface. This polarisation is the result 
of VEGFR-1 and -2 having distinct functions within their tissue microenvironment; 
VEGFR-1 induces a cytoprotective response and VEGFR-2 causes an increase in 





1.4.2.3 - Invasion and migration 
The EC that senses the highest concentration of VEGF via its binding to VEGFRs on 
the EC (mainly VEGFR1 and -2) becomes the pioneering tip cell [32], and displays a 
relatively much greater number of VEGFRs on its surface [30] (Figure 1.8). These are 
presented on long filamentous projections from the plasma membrane called filopodia 
[39]. Intracellular cascades take place when VEGF-A binds its receptor, involving the 
secretion of large amounts of proteolytic enzymes from the filopodia important for 
digesting the surrounding stoma. The local concentration of VEGF-A is detected by the 
receptors, which can sense the gradient of VEGF and align itself to the area of highest 
concentration [30]. Integrins are presented along the filopodia membrane, which bind to 
the underlying substratum and generate traction. Contraction of acto-myosin fibres 
within the cell that are bound to these cell-ECM junctional complexes pulls the tip cell 
towards the stimulus. Cell-ECM contact complexes present at the rear of the cell must 
be endocytosed and recycled for the rear to be pulled up along with the front of the cell. 
The cell rolls over its integrin complexes generated at the leading edge of the cell and 
there is productive movement forward. Simultaneously, cells behind the tip cell 
proliferate as they follow the leader cell; they must retain their cell-cell junctions for a 
continuum of ECs to be created, which becomes the endothelial stalk. This tip-stalk 
morphology is dependent on Delta-Notch signalling; the activation of VEGFRs in the tip 
cell induces Delta-like-4 (Dll4) expression [39,40]. This cell bound factor then binds and 
activates notch receptors present on the cell membrane of stalk cells. This represses 
expression of VEGFR2 on the stalk cells, making them less responsive to the VEGF-A 
gradient and hence less migratory relative to the tip cell [39,40]. 
 
1.4.3 - Lymphatic system development 
Lymphangiogenesis, lymphatics system development, occurs early on in 
embryogenesis and involves both angiogenesis and vasculogenesis [26]. Venous 
precursor cells in the embryo are the prerequisite for lymphatic development [41]. In a 
step-wise process and beginning with vECs, lECs are formed from the differentiation of 
vECs which then bud out to form lymph sacs. Lymph sacs are initial lymphatic 
structures from which the lymphatic vasculature stems from [42]. During development 
these sacs remodel into tubules, which permeate surrounding tissues and organs.  
       Early in embryonic development, PROX1 homeobox gene expression is 





























Figure 1.8 – Selection and auto-promotion of tip cell during angiogenesis. a) 
The tip cell migrates towards the area of highest VEGF-A concentration, 
complementing this gradient by expressing a higher concentration of VEGFR2s. 
Both concentrations are gradiented with low concentrations of VEGF-A 
accompanied by low concentrations of VEGFRs on the stalk cells. b) Tip cell 
selection replies upon Delta-Notch signalling. Activation of Notch receptors on 
stalk cells results in its proteolytic cleavage and release of its intracellular domain. 
This is transported to the nucleus and represses genes for VEGFR2, inhibiting tip 




































a transcription factor heavily involved in lymphatics development and SOX18 and 
COUP-TFII, expressed by blood ECs at the CV, are responsible for Prox1 expression 
[41]. This is the commitment stage for vECs to become lECs, which now become lEC 
progenitors. PROX1 expressing ECs start to bud from the CV in a polarised manner 
[43]. Budding migration away from the CV requires mitogenic stimulation of the lEC 
progenitors. VEGF-C is expressed by mesenchymal tissue in a gradiented manner to 
bind to its receptor, VEGFR-3, present on the surface of the lEC progenitors. VEGFR-3 
expression is maintained by PROX1, and binding of its ligand allows the alignment of 
lECs towards avascularised tissues. The interconnected budding of the lECs continues 
until they assemble together into lymph sacs. These sacs are intermediate structures 
and are the main source of lECs required to form the entire lymphatics system [41]. 
They are luminal structures with a monolayer of lECs, similar to structures formed 
during vasculogenesis. As with vasculogenesis, lumen formation occurs when 
intracellular vacuoles formed by endocytosis coalesce and form a channel through 
interconnected cells. During the formation of this structure, there is separation of the 
circulatory and lymphatic systems [43]. These lECs then proliferate and sprout away 
from the intermediate structure to form the entire lymphatic vasculature, utilising 
angiogenesis. lECs migrate towards mesenchymal tissues in a continuous fashion, the 
individual cells joined to each other via VE-cadherin adhesion junctions [41,44].  
       Not all lECs expressing PROX1 bud from the CV; a small subpopulation of cells 
does not express VEGFR-3 and hence are not migratory. These cells remain in place 
and form the connective lymphovenous valves between the lymph sacs and adjacent 
veins [41]. These valves are connective apertures and are continuous with the vECs of 
the vein, forming a double layer of lECs being present underneath a layer of lECs 
continuous with the lymph sac. They allow for a conduit of lymph to enter the blood 
stream via subclavian veins whilst preventing the reflux of blood into the lymphatics 
system [41]. The molecular mechanism of separation of the two vascular systems still 
remains unclear, however it is well established that platelet activation is a key stage in 
the process. Several molecular players have been shown to be involved in the activation 
and aggregation of platelets crucial for separation of the lymphatic and blood 
vasculatures, including podoplanin (PDPN) [41]. PDPN is expressed by budding lECs, 
suggesting a potential signalling route for vascular separation from lEC budding. 
Besides PDPN, Syk tyrosine kinase and its adaptor, SLP-76, are the main players that 
promote lymphatics separation from the blood vasculature and are expressed mainly by 
















lECs continue to proliferate and migrate, expanding the lymph sacs into the surrounding 
mesenchymal tissue. The lymphatic vasculature quickly expands throughout most of the 
developing embryo [43]. During maturation of this vasculature, the lECs must further 
differentiate into specialised lymphatic structures, such as collecting lymphatic vessels 
or lymphatic capillaries [41]. As embryonic development progresses, the lymphatic 
vasculature begins to express different gene products in a step-wise manner [43]. 
Collecting lymphatics downregulate their markers for lymphatic capillaries, namely 
PROX1, VEGFR-3 and LYVE1. They also upregulate genes to secrete ECM and induce 
SMC migration and proliferation to cover the vessels. Collecting lymphatic cells that 
form bicuspid valves however maintain their expression of PROX1. The interaction of 
ECM components with ECM receptors, such as fibronectin with integrin α9, contributes 
to the development of lymphatic vasculature. Similar to vasculogenesis and 
angiogenesis, additional guidance cues are needed as well as the VEGF family [43]. 
Sema3a, a neuronal axonal guidance protein, binds to the receptors Nrp1 and Plxna1 
present on the collecting lymphatic vessels and lymphatic valves [43]. This is crucial for 
proper lymphatic vessel and valve development. In addition, ephrin signalling is required 
for vessel development and maturation. Ephrin B2 interaction with its Eph receptor on 
the lymphatic vessels stimulates specialisation of the vessels into collecting vessels [43].  
 
 
1.5 – Endothelial cell functions 
Primitive concepts of ECs were basic and underappreciated. The endothelium was 
merely seen as an inert lining of blood vessels, providing a protective and non-adherent 
barrier between the blood and surrounding tissue [4] that is involved in transport of 
substances across. Key observations taken in recent decades have shown that the 
endothelium lies at a hub of homeostasis [17], being involved in many key physiological 
processes. Serving as an interface between the blood and lymph and surrounding 
stroma, it controls the passage of substances between the two bodies. Thus, it controls 
the uptake of nutrients and disposal of waste products, as well as the initiation and 
regulation of inflammation [4]. The volume of luminal fluid passing through any particular 
area of the capillary network varies in accordance to physiological requirement, and 
these changes are brought about via vascular contraction or dilation. The endothelium 
behaves like a middle-man, controlling vascular tone in response to signalling factors 
present in the luminal fluid. If the endothelium is damaged or it detects damage to the 
24	  
	  
surrounding stroma, ECs are responsible for eliciting a blood coagulative response to 
avoid excessive blood loss from the circulation. Simultaneously, the tissue is induced 
into a state of repair before the blood clot is dissolves to return the vasculature to 
normal functioning. A new capillary network may be needed to complete tissue repair, 
which is intimately dependent on the detection of, and response to, various signalling 
molecules by ECs. Formation of the initial and dynamically changing vasculature 
network is also reliant on the action of ECs. 
       The microvasculature in different parts of the body are composed of organ-specific 
ECs, which have differentiated to become morphologically and physiologically distinct 
from one another [12]. Every organ in the body has its own unique functions, which are 
dynamic and versatile depending on both systemic and local environmental changes. 
Their vasculature must reflect this as they serve as the gatekeeper controlling organ 
microenvironments by forming an interface between the circulation and surrounding 
tissue. Their functions, therefore, differ depending on their organotypic micro-
environment. The endothelium must be adaptable and responsive to the requirements 
of that particular organ [12]. In this way, they are responsible for many physiological 
functions, and their dysfunction is implicated in many pathologies.       
 
 
1.5.1 - Transport of nutrients 
The selective transport of molecules between the blood stream microvasculature and 
extravascular interstitium is reliant on the extent of the integrity of the endothelium. The 
continuous architecture of the endothelium, held together by tight junctions, generates a 
barrier-like function that exists ubiquitously in the human body [12]. While this is true for 
most vasculature, ECs in capillaries form three different types of endothelium, each with 
different functions.  
       Continuous non-fenestrated capillaries form a secure, fence-like sheet that only 
permits the diffusion of water, small solutes and lipid-soluble molecules across their 
endothelial lining [12] (Figure 1.10). Larger fluid components, such as plasma proteins 
and circulating cells, cannot pass through and remain in the blood stream. Larger 
components of the blood that are required by tissues to metabolise, such as amino 
acids, pass through the endothelial monolayer via transcytosis by selective transporters 
on the monolayer’s cellular surfaces [4]. These are regulated by specific mediators such 
as insulin, nitric oxide (NO) and hypoxia induced factors, and the expression of these 
transporter molecules reflects the metabolic requirements of the subendothelial tissue. 
A specialised form of the continuous endothelium is the blood-brain barrier (BBB) in the 
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central nervous system (CNS) [12]. Neuronal cells do not have the capacity to replicate, 
and as a result are more vulnerable to pathogenic and other blood-borne toxins and 
fluctuations in blood constituents. The death of many cells in the CNS would be 
catastrophic to the health of an organism and could result in severe neurological 
diseases such as Alzheimer’s disease. The micro-vasculature in this tissue must 
therefore tightly regulate the movement of ions, molecules and cells between the intra- 
and extra-vasculature regions. Capillaries in the CNS exclude pathogens, toxins, drugs 
and most other large molecules [12]. Aside from specialised tight intercellular junctions, 
ECs that make up the BBB have surrounding layers of pericytes and astrocytes [45]. 
Pericytes have long extensions of their cellular body which contact the abluminal 
surface of the capillary ECs at discrete points, however most of their body is embedded 
in the basal lamina surrounding the vessels. They contain contractile proteins, allowing 
for the regulation of the capillary diameter via cellular contractions/dilations [45]. 
Astrocytes are star-shaped glial cells that, among other functions, biochemically support 
the endothelium within the CNS. They promote barrier functioning of the BBB and make 
up a cellular link between the blood vessels and the electrochemistry of the neuronal 
system. They too have long polarised extensions that cover the blood vessel and 
pericyte fibrils. This coupling of the vasculature and CNS allows for vessel diameter 
regulation via contraction/dilation of the surrounding pericytes [45].   
       The intercellular tight junctions as well as surrounding cellular sheath around CNS 
capillaries that expel many molecules needed by neuronal cells means that extracellular 
transport systems are required. Highly specific transporters present on the EC plasma 
membrane import nutrients from the blood down their concentration gradient and traffic 
them into the CNS for cellular metabolism. These transporters are highly specific for 
their substrate, many of which are solutes. ECs in the CNS are highly enriched in 
glucose transporter 1 (GLUT1) at their apical surface, transporting glucose into the brain 
parenchyma from the blood [45]. Cerebral tissue is highly reliant on glucose as its 
source of ATP, relative to other sources of energy storage, and so this transporter is 
highly expressed on its micro-vasculature. Fulfilling 8-10% of the brain’s energy 
requirements, lactate also plays a critical role in neuroenergetics [46]. It is able to enter 
the cerebrum via the monocarboxylate transporter 1 (MCT1), present at the apical 
cellular surface, which can traffic other monocarboxylates across. Lactate can be fully 
oxidised within brain cells during the TCA cycle after being converted to pyruvate by 
lactate dehydrogenase, generating 30-36 molecules of ATP [46]. During periods of 
hyperlacticaemia, such as during moderate to intense exercise, lactose may provide up 
to 25% of the ATP in cerebral cells [46]. The rate of lactose uptake and oxidation 
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increase, substituting for glucose uptake and oxidation so that it can be utilised to a 
higher extent in muscle cells. Transporters are also required to necessitate the traffic of 
amino acids across the BBB. LAT1 is responsible for the influx of large neutral amino 
acids [47], such as tryptophan and tyrosine, important for anabolic processes within the 
cell as well as catabolic metabolism during cellular starvation. Several pharmaceutical 
drugs are also substrates for this receptor [47], including L-DOPA, a precursor molecule 
to important neurotransmitters such as dopamine. L-DOPA is commonly used in the 
clinical treatment of Parkinson’s disease. Drug delivery across the BBB is limited due to 
the tightly regulated cellular permeability, and so pharmaceutical drugs that complement 
luminal receptors are the main way of introducing a cerebral cellular response. In 
contrast, CAT1 transports cationic amino acids across the BBB into cerebral tissue. 
Other membrane receptors include the transferrin receptor and low-density receptor-
related lipoprotein, among others. Receptors required for efflux of waste products 
generated from cellular metabolism are also apically localised in neural cells [45]. 
       Fenestrated capillaries differ from continuous non-fenestrated capillaries in that 
they have intracellular pores joined by diaphragms [12] (Figure 1.10). The purpose of 
the diaphragm is to speed up the exchange of water and allow the passage of solutes 
that would not otherwise pass through a continuous capillary due to size restrictions. 
Small peptides can pass between the blood and interstitial fluid, making these vessels 
suitable to provide vasculature for tissues such as endocrine organs and the intestinal 
tract. Hormones enter the blood stream from endocrine glands to elicit systemic cellular 
responses. The extent of hormone secretion into the blood stream is partly controlled by 
the number of ECs and associated fenestrae. EC coverage is controlled by VEGF 
secretion, with VEGF binding to VEGFR2 and eliciting a signalling response that 
promotes EC proliferation and migration. VEGF, in turn, is upregulated in endocrine 
glands by hormones such as TSH, ACTH and FSH. These act to increase transcellular 
transport by increasing the number of ECs and intact fenestrae. Reducing the secretion 
of hormones into the blood stream involves low levels of stimulating hormones, reducing 
the number of ECs and fenestrae.  
       Sinusoidal capillaries have characteristic irregular shaped ECs and intracellular 
gaps with an incomplete basal lamina [12] (Figure 1.10). These gaps create conduits for 
cells and large molecules between the blood stream, lymph and interstitial fluid. Such 
access to vasculature lumen is utilised in an immune reaction, where an adequate 
response to infection relies on the production and secretion of immune cells. These cells 
are made in the bone marrow and mature in secondary lymphoid organs (SLO) [18]. To 
reach the area of pathogenic infection, these cells must be able to exit from SLOs via 
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efferent lymphoid vessels and enter capillaries via passing through the interstitial space. 
The open pores in the endothelial lining allows white blood cells, such as lymphocytes, 
to exit from the lymphatics and passively enter the circulatory system. Sinusoids are 
also present in the spleen, liver and several endocrine organs such as the pituitary 
gland. This type of capillary is involved in processes that require rapid physiological 
responses, as so it is the organisms best interest to have maximal exchange of 
components between the capillary lumen and surrounding interstitial fluid. The flow of 
blood to the sinusoids is slower, allowing a greater amount of time for fluid constituents 
to pass the EC barrier.  
 
1.5.2 – Haemostasis 
Maintenance of fluid, circulating blood around the blood vasculature is essential for 
normal physiological functioning. Blood must be fluid enough that it can be pumped 
around the body at an optimal rate that does not cause too much strain on the heart and 
vascular muscles. However, to prevent excess blood loss when a blood vessel is 
damaged, blood in the local environment must alter its viscosity and form a blood clot 
around the site of injury. This is haemostasis. In the normal physiological state, there is 
a careful balance of hypercoagulability and hypocoagulability in the blood [48]. 
Imbalances in this equilibrium results in pathological disorders. Some of these disorders 
are mainly caused by endothelium dysfunction; ECs, under normal physiological 
conditions, provide an antithrombotic surface to prevent inappropriate clot formation [4]. 
Inappropriate activation of the clotting cascade results in a thrombus (blood clot) which 
may block the vessel in which it was made. On the other hand, if the endothelium is 
deficient in a component of this same cascade, failure of coagulation may occur which 
makes blood loss a more likely and severe event [7].  
       The endothelium forms an interface between the blood and tissues. It is 
strategically located so that it can interact with components of the blood to regulate its 
haemostatic balance, while detecting loss to its own integrity. There are two main 
stages to haemostasis [7]. An initial plug is formed to quickly and temporarily block the 
site of endothelial lesion. This is made entirely of platelets – anucleate cell fragments 
that circulate inactive in the blood. These are activated on stimulation by components 
released by the damaged endothelium and adhere together and to the site of injury to 
form a plug. Secondary haemostasis serves to form a stable mesh of red blood cells 
and insoluble plasma proteins around the platelet plug, initiated by the conversion of 




























Figure 1.10 - Three major types of capillaries. (A) Continuous capillaries, mainly 
present at the BBB in the CNS, have tight cell-cell junctions and a continuous basal 
lamina to prevent the free passage of large molecules. Transport of anything that isn’t 
water, small solutes or lipid soluble molecules can only pass though via regulated 
transcytosis. (B) Fenestrated capillaries have gaps in the EC monolayer, but which are 
covered with a diaphragm. There is still a continuous basal lamina and so there is not 
free passage of all molecules, however some peptides are able to cross these 
capillary networks. (C) Sinusoidal capillaries have complete intercellular clefts, made 
by intercellular gaps and a discontinuous basal lamina. This allows free passage of 
molecules, as occurs in the spleen to allow rapid movement of immune cells into the 





1.5.2.1 - Primary haemostasis 
Seconds after EC damage, platelets activate and begin to adhere together and to the 
site of damage [4]. Their activation relies upon stimulation of receptors on their surface. 
Collagen is the ligand for the GPVI receptor, present on the surface of platelets. 
However, as it exists in the subendothelial tissue, it is only available to bind upon 
subendothelial exposure during endothelial injury. The binding of collagen to GPVI 
activates the platelets, which undergo a morphological alteration from a small, disc-like 
shape to a more elongated shape with long, fibrillar membrane extensions. As well as 
changing their shape, the platelets expose integrins on their surface, which are able to 
bind to multiple ligands causing platelet aggregation and ECM adherence [49]. The most 
important integrin is αIIbβ3, which binds several subendoethelium components such as 
fibronectin, collagen, vitronectin and fibronectin as well as von Willebrand factor (vWF) 
[7]. This forms an expansion of platelet-platelet and platelet-endothelium adhesions [7]. 
Another receptor important for platelet activation is GPIb-IX-V, which binds to vWF via 
its GPIbα domain. vWF is a large multimeric adhesive glycoprotein complex that is 
stored in an immobilised manner in the cytosol of ECs, in organelles known as Weibel-
Palade bodies (WPBs). It is also stored in this way in α-granules inside platelets 
themselves. vWF is stored as highly compact tubules, essential for physiological 
function of the factor [6]. On endothelial injury, these WPB expose vWF, which rapidly 
unfolds into ultralong strings that dock and bind to adhesive molecules on the 
endothelium and platelets. This forms a network of adhesions between platelets 
themselves and between platelets and the endothelium. Its release from α-granules is 
triggered by several agonists such as collagen and thrombin, revealed upon endothelial 
damage [6][7]. 
 
1.5.2.2 - Secondary haemostasis 
This secondary process composes a complex, sequential activation of clotting factors 
present in the blood plasma [18]. These are serine proteases, synthesized in the liver, 
which circulate in the blood in an inactive form. An intact endothelium prevents the 
activation of these factors as it presents anti-coagulants on its surface. Thrombomodulin 
present on normal ECs binds to thrombin, and this complex binds to and activates 
protein C. Protein C acts as a serine protease, cleaving and inactivating crucial 
prothrombotic factors involved in clot formation. The binding of thrombin to 
thrombomodulin also acts to convert thrombin from a procoagulant to an anticoagulant 
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[11]. Furthermore, HPSGs on EC surfaces prevent platelet aggregation, stopping the 
progress of the initial platelet plug and hence the platform for secondary haemostasis. 
Heparin also stimulates the activation of antithrombin to inactivate any thrombin that is 
not in a complex with thrombomodulin [7]. In the event of exposure of the 
subendothelium to plasma components, prothrombotic plasma factors activate. Two 
pathways exist, one activated by factors intrinsic to the plasma and the other extrinsic, 
which result in the activation of factor X, converting prothrombin to thrombin [4]. 
Thrombin cleaves the soluble plasma protein fibrinogen to form insoluble fibrin. These 
polymerise to form long strands creating a mesh-like web of insoluble fibres that can 
trap cells and other blood constituents. The localised exposure of subendothelium 
ensures that both the extrinsic and intrinsic clotting pathways occur only at the site of 
endothelial damage [11]. When the endothelium has been fully repaired, it reverts back 
to an anticoagulatory state and further clotting is prevented. The original clot is 
dissipated by plasmin, activated from its zymogen plasminogen after exposure to blood 
clots, which degrades the fibrin mesh [11].  
 
1.5.2.4 – Inflammation 
Inflammation is a physiological response to injury caused by a multitude of agents and 
is part of the innate immune reaction [17]. This is a rapid response system, which uses 
non-specific methods of pathogen recognition. Inflammation has evolved in higher 
organisms to contain and eliminate the agents which caused the tissue damage and to 
remove any damaged and dead tissue. It also provides a route for regenerative agents 
to heal the region of injury and restore normal tissue architecture [49]. There are four 
main characteristics of inflammation; redness, heat, swelling and pain [17]. A fifth 
distinction is loss of function of the inflamed area, described later than the other 
characteristics and caused by spatial restrictions brought about by the swelling and/or 
pain preventing proper movement. These distinctions are the direct consequence of the 
inflammatory process. The main objective of inflammation is to increase blood flow to 
the area of injury to allow for mass movement of immune cells and agents across the 
endothelium and into the surrounding tissue. The endothelium is the interface between 
these immune cells and site of injury, and hence has a major role in the inflammatory 
process. All the cellular responses that occur during acute inflammation are the direct 
result of EC activation [49]. ECs serve to recruit leukocytes to the area of infection and 
regulate their behaviour and activity by releasing cytokines and growth factors. 
Adhesion molecules expressed on ECs allow the diapedesis of immune cells across the 
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endothelial lining and into the tissue to carry out their function [17].  
       Inflammation is first triggered directly through pathogen recognition by immune 
pattern recognition receptors (PRR), or indirectly by complement cascade activation. 
This is a system of plasma proteins which sequentially activate after immune interaction 
with a pathogen [50]. The resulting activated molecules, C3 and C5, are cleaved into 
C3a and C3b, and C5a and C5b respectively. C3a together with C5a activate a local 
inflammatory reaction via mast cell degranulation [11]. Conversely, mast cells can 
directly recognise pathogens using their PRRs, such as Toll-like receptors (TLRs), 
which evokes a signalling cascade resulting in their degranulation [51]. This 
degranulation releases cytokines such as TNF-α, CXCL10, IL-8, histamine as well as 
prostaglandins and leukotrienes [51]. These agents are released into the interstitial 
space, which act upon local ECs to upregulate the secretion of adhesion molecules to 
the apical surface.  
       The recognition of the site of extravasation by immune cells is brought about by 
these adhesion molecules, which act sequentially to mediate leukocyte contact and 
migration through the vascular wall [17] (Figure 1.11). These adhesion molecules are 
coordinated by several chemical mediators, such as chemokines, and are present to 
promote leukocyte rolling, tethering and capture prior to trans-migration through the EC 
wall. Initial tethering is brought about by members of the selectin family [17]. L-selectin is 
constitutively presented on almost all leukocytes, while E-selectin is presented on ECs 
and P-selectin on platelets and ECs only after cytokine stimulation. L-selectin binds to 
sulphated sialomucin groups [52] on the ECs during their routine vascular rolling, a 
process that enables chemokine detection. They have a glycocalyx rich in 
proteoglycans which tether these chemokines in place to allow their presentation to the 
rolling leukocytes. When EC’s detect chemokine stimulation, they present P-selectin 
and/or E-selectin on their surface. These bind to P-selectin glycoprotein ligand-1 
(PSGL-1) and E-selectin ligand-1 (ESL-1) respectively [52]. This is tighter binding than 
the initial interaction between L-selectin and EC glycoproteins and allows time for 
receptors on the surface of the leukocytes to sense chemokine gradients from ECs at 
the site of injury.  
       The interaction between the leukocyte and EC cell adhesion molecules, as well as 
presentation of chemokines to the leukocyte, causes activation of the leukocyte. LFA-1 
and α4β1 integrins on the surface of the leukocyte undergo a conformational change, 
from an inactive closed conformation to an open, active state displaying the ligand 
binding domain, the I domain [49]. This reaction is brought about by inside-out signalling 
where receptor-ligand binding triggers a signalling response inside the cell [50]. The 
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binding of integrins is much higher affinity than with selectins, and as a result the 
leukocytes are pulled towards the vascular endothelium much more tightly [52]. 
Activation of ECs by various chemokines also upregulates the expression of E-selectin, 
and ICAM-1 and VCAM-1. The latter are cell adhesion molecules, which bind 
complementary molecules on leukocyte membranes. Simultaneously, there is an 
increase in vascular leakiness brought about by contractions in EC actin filaments 
attached to tight and adherans junctional complexes [49]. This contraction is caused by 
the docking of neutrophils, via integrins, and pulls the cell-cell junctions away from each 
other, opening intracellular gaps and allowing plasma proteins and leukocytes to enter 
the interstitial fluid. The leukocytes are further directed through these inter-cellular gaps 
via platelet/EC adhesion molecule-1 (PECAM-1) [52], a protein present on ECs, 
leukocytes and platelets. It is evenly distributed on leukocyte cell membranes, but only 
at the lateral boarders of ECs to form cell-cell adhesives. Hence it is involved in guiding 
these leukocytes through the intercellular gaps during diapedesis. Once past the 
endothelial lining, leukocyte migration through the underlying stroma is reliant on matrix 
proteins binding to leukocyte adhesion molecules.  
       In the interstitial space, these immune cells destroy invading pathogens and clear 
away debris by means of phagocytosis [17]. They have chemokine receptors on their 
surface which detect a chemokine concentration gradient. These chemokines are 
released from damaged cells and hence guide the immune cells toward them [53]. 
Antibodies and complement can also cross the endothelial wall contained within blood 
plasma, helping to opsonise pathogens and enhance inflammation. The capacity for 
immune activity is greatly enhanced by vasodilation of the capillary network around the 
site of damage. This is brought about by histamine and prostaglandins, acting on SMCs 
surrounding blood vessels near the region of tissue damage. If the region is healed 
successfully and functionality is restored to the tissue, the inflammatory response 
diminishes as there is no further release of chemical mediators. However, if the 
abnormal conditions persist post the acute inflammatory response, the process persists 
and the repertoire of immune cells migrating to the tissue changes. Cells of the adaptive 
immune response replace leukocytes, including effector and memory T cells. If this 
response fails to clear the infection, inflammation persists, gaining a different set of 
characteristics than before [54]. The tissue enters a state of chronic inflammation in 
which there is continual tissue damage and repair, caused as a consequence of the 



































Figure 1.11 – Leukocyte extravasation. Pathogen detection results in mast cell 
degranulation and macrophage activation, leading to release of pro-inflammatory 
mediators. This activates ECs, which upregulate their expression of selectins on 
their luminal surface, which can bind their ligands that are constitutively present on 
the surface of neutrophils. This results in an intracellular signalling cascade within 
the neutrophil, resulting in a conformational change in their transmembrane 
integrins, which open into an active conformation. Activation of ECs by pro-
inflammatory mediators upregulates expression of ICAM-1 and VCAM-1, which 
bind to LFA-1 and α4β1 integrins respectively. This high affinity binding allows 
interaction between PECAM-1 on both the leukocyte and lateral EC surfaces, 
directing the leukocyte through the intercellular endothelium gaps and into the 
interstitial space. Cytokines released from the site of damage act as an attractive 
stimulus for migration of these translocated leukocytes, which then attempt to 
restore the tissue back to proper function. Image adapted from Kunkel and 




1.6 – Endothelial cells in pathology 
An average adult contains an endothelial surface of approximately 1 to 6 x 1013 cells 
that covers a surface area of approximately 1 to 7 m2 [3]. It penetrates every organ and 
expands its vast network of vessels to reach every tissue, with every cell being a few 
microns away from vasculature. Its longest standing and primary role is maintaining a 
selectively permeable barrier between the blood/lymph and surrounding interstitial fluid. 
It also has roles in maintaining haemostatic homeostasis by means of balancing its 
antithrombotic and prothrombotic effects during normal physiology, tipping the balance 
towards a local prothrombotic response during endothelial injury. In addition to 
promoting local blood clotting at the site of injury, ECs will also induce inflammation in 
that area to clear any infections and heal the wound. Blood flow during injury and 
physiology is regulated by the endothelium via secretion of vasodilatory factors such as 
nitric oxide (NO) and prostacyclin, or by secretion of vasoconstrictive factors such as 
thromboxane and endothelin-1 [55] in response to various stimuli. Hence, ECs have a 
pivotal role in maintaining whole body homeostasis. Imbalances in EC responses leads 
to endothelial dysfunction, which contributes to the establishment and progression of 
many diseases. Having a pivotal role in inflammation, dysfunctional EC functioning 
leads to dysfunctional inflammatory responses. Chronic inflammation exacerbates fat 
deposition in artery vessel walls, leading to atherosclerosis. This will be the main focus 
of the role of the endothelium in disease, however it has roles in various other 
pathologies. These include hypertension, sepsis, thrombosis and cancer metastasis. 
 
1.6.1 - Atherosclerosis  
Atherosclerosis is a leading cause of mortality and morbidity in the developed world [56]. 
It is characterised by thickening of the intimal layer due to build-up of fatty plaques at 
focal points in large and medium-sized arteries [57]. These impinge on the vessel 
lumen, reducing the volume of blood able to pass, and may rupture causing acute 
vessel occlusion due to thrombosis [56]. This is responsible for pathologies such as 
myocardial infraction and stokes, causing vital organ ischaemic damage [58]. The extent 
of the damage caused by the disturbed blood flow to these organs depends of the 
magnitude and duration of the disruption in the blood supply [58].  
       The fatty plaques are composed of a central lipid core, composed of cholesterol 
and cholesterol esters [56], with an overlaying fibrous tissue cap, enclosed within the 
arterial endothelium [57]. The underlying molecular mechanism involves an imbalance in 
lipid metabolism and chronic inflammatory response at the arterial wall. This results in 
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an accumulation of oxidised lipid-laden macrophages (foam cells) which die via 
apoptosis and release their fatty deposits in the intima of the artery wall. The pools of 
oxidised lipids present as pathogens to the immune system, and so a low-grade 
inflammatory response is triggered. This activates ECs and vascular smooth muscle 
cells (VSMCs) which results in the bulk passage of immune cells across the 
endothelium and into the interstitial space. The SMCs take on a myofiboblast 
characteristic by the deposition of collagen and elastin after stimulation by growth 
factors [58]. This forms a fibrous cap on top of the lipid core, and repeated cycles of lipid 
deposition, inflammation, SMC proliferation and collagen deposition results in gradual 
increase of plaque volume and artery wall weakening [57]. This manifests into either 
chronic or acute vascular diseases. 
       Atherosclerosis pathogenesis is a two-stage process. First, the arterial wall is 
injured due to haemodynamic forces, chemical attack, mechanical denudation, immune 
complex deposition or diabetic hyperglycaemia [56,57]. The proceeding step is a 
response by the tissue to the injury that results in intimal thickening. There are regions 
of the cardiovascular system that are predisposed to atherosclerotic lesions. These 
organise into lesion-prone areas of the arterial tree [59]. These regions are 
characterised by the biomechanical forces acting on them, which translate into different 
transcriptomics resulting from the type of blood flow interacting with the area of vascular 
wall. It appears that atherosclerotic plaques form where blood vessels branch or curve. 
These regions have highly disturbed blood flow, with high oscillatory shear stress index. 
In contrast, unbranched arteries with uniform laminar shear stress are plaque resistant 
[59]. Uniform shear force results in the activation of nitric oxide synthase (eNOS), which 
catalyses the production of nitric oxide (NO) from L-arginine. NO in turn activates 
soluble guanylate cyclase in SMC, converting GTP to cGMP (Figure 1.12). cGMP 
activates a protein kinase and subsequent signalling cascade, resulting in a decrease in 
phosphorylation of myosin light chains and hence a decrease in the contraction of 
SMCs. This vasodilation lowers the pressure of blood flow in the artery and means there 
is a lower chance of arterial damage and hence inflammatory response. In addition, NO 
stabilises IκB, an inhibitor molecule for NFκB (Figure 1.12). NFκB is a transcription 
factor which mediates a pro-inflammatory cellular state. Hence, constitutive production 
of NO will stabilise IκB and maintain the EC in an anti-inflammatory state.  
       Inflammation that results from EC injury or regions of highly disturbed blood flow 
contributes to the initiation and progression of atherosclerosis. ECs upregulate cell 
adhesion molecules and undergo vasodilation and increased permeability. A thrombotic 
response is also activated as mast cells degranulate. This is a normal physiological 
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process as the body attempts to eliminate any infectious agents in the damaged tissue 
and initiate a repair process. However, prolonged injury due to high blood pressure, as 
well as low levels of NO in ECs with highly disturbed blood flow, will result in chronic 
inflammation. This increased blood flow and permeability of the vasculature will, as a 
consequence, increase the amounts of macromolecules such as low-density lipoprotein 
(LDL) that enter the tissue from the plasma [57]. LDL is a transport lipoprotein that 
carries cholesterol and other lipids in the blood and delivers the cholesterol to the liver 
and other tissue. LDL and its constituents can enter the sub-endothelium via 
intercellular pores (Figure 1.13). It is attracted by the negatively charged ECM, as it is 
itself positively charged. The accumulation of pools of LDL within the subendothelial 
matrix is greater when there are higher circulating levels of LDL in the plasma [56], 
hence diet has a large effect on the development of atherosclerosis. LDL retention in the 
sub-endothelium depends on interactions between the LDL carrier, apolipoprotein B 
(apoB), and the proteoglycan constituents of the matrix [60]. Once in the sub-
endothelium, native LDL undergoes oxidation, among other modifications, by reactive 
oxygen species (ROS) produced from vascular cells. Oxidised-LDL (ox-LDL) is seen as 
‘foreign’ to the body and triggers a pro-inflammatory response. ECs upregulate their 
expression of ICAM-1, VCAM-1, P-selectin, E-selectin and PECAM-1 in response to 
pro-inflammatory cytokines, which are presented on the cellular surface. The interaction 
of the selectins with carbohydrate ligands on the monocyte cell membrane mediates 
monocyte integrin expression. Heterotypic interaction of cell surface adhesion 
molecules between the monocytes (VLA-4) and ECs (ICAM-1, VCAM-1 and PECAM-1) 
is a prerequisite for monocyte diapedesis across the endothelial lining (Figure 1.13). 
Monocyte chemotactic protein-1 (MCP-1) and macrophage colony-stimulating factor (M-
CSF) are secreted by ECs in response to ox-LDL [60]. These are released into the 
interstitial space and promote monocyte chemotaxis across the endothelium and their 
proliferation and differentiation into macrophages respectively.  
       Scavenger receptors present on the differentiated macrophages recognise a wide 
variety of ligands. They are multifunctional PRRs and are able to recognise and uptake 
oxidised-LDL, as well as cholesterol crystals cell debris etc [61]. Recognition of these 
ox-LDLs induces an inflammatory response by the macrophage, which releases more 
MCP-1 and hence further recruitment of monocytes. Activated macrophages also 
produce ROS which propagates further LDL oxidation [56]. In this positive feedback 
loop, macrophages begin to accumulate modified lipids in their cytosol and these cells 
cluster under the endothelial layer in the vessel. In time, these foam cells begin to die by 




























Figure 1.12 - Laminar flow (high shear force) results in the increased 
generation of NO. eNOS is activated by changes in intracellular Ca2+, created by 
shear forces or receptor-mediated signalling. eNOS is an enzyme that catalyses the 
conversion of L-arginine to NO. Elevated NO levels, as with shear vascular force, 
stabilises NFκB due to NO binding to and stabilising its inhibitor molecule, IκB. NFκB 
cannot bind DNA to upregulate proinflammatory cytokine gene expression, hence a 
pro-inflammatory response is attenuated. NO also activates GC, converting GTP to 
cGMP, resulting in less phosphorylation of myosin light chains and subsequent 
reduction in SMC contraction. Adapted from Physiology of the endothelium. H. F. 





















Figure 1.13 – Pathogenesis of atherosclerosis. LDL is able to cross the 
endothelium via intercellular pores. Once inside the interstitial space, LDL is oxidised 
and is recognised and taken up by macrophages via their scavenger receptors. 
Macrophages which have taken in ox-LDL become foam cells, fatty forms of 
macrophages which are indicative of atherosclerosis onset and progression. The 
recognition of ox-LDL in the sub-endothelium triggers an inflammatory response, which 
leads to further accumulation of macrophages in the interstitial space and foam cell 
formation. These foam cells die by apoptosis and release their intracellular lipids into a 
growing necrotic core beneath the plasma membrane. Cytokine stimulation of SMC 
contributes to their proliferation and migration to regions just below the endothelial 
lining. This SMC accumulation, together with the release of elastin, collagen and 
mucopolysaccharides by SMC, promotes thickening of the fibrous cap. Image from 




forming an ever-growing necrotic core. The prolonged activation of ECs together with 
macrophages, platelets and SMC will induce an adaptive immune response. T-helper 
cells enter the interstitial space via CAMs and interact with CD40 receptors via their 
CD40L (CD40 ligand) on their cell surface. This results in a signalling response within 
the cells, upregulating the expression and secretion of cytokines such as interferon-γ 
(IFN-γ) and metalloproteinases. IFN-γ promotes SMS proliferation, allowing SMSs to 
migrate and proliferate in-between the endothelium and lipid core. Other growth factors, 
such as platelet derived growth factor (PDGF) are secreted by macrophages and ECs to 
promote a chronic state of inflammation and these also induce SMC proliferation [56]. A 
chronic inflammatory state induces SMC to lay down elastin, collagen and 
mucopolysaccharides, contributing to the formation and stability of the fibrous cap [57]. 
 
1.6.1.1 - Clinicopathologic consequences of atherosclerosis 
Atherosclerotic plaques develop over the lifetime of a patient, but symptoms only show 
when the luminal volume is reduced by 50-75% [57], or during an acute rupture or 
embolisation of the plaque. Expansion of the atheroma may impinge on blood flow to 
vital organs and tissues. This reduces oxygenated blood to regions downstream of the 
stenosis, which may not have clinical symptoms. At a tipping point, known as critical 
stenosis [56], the occlusion is so severe that demand for oxygenated blood exceeds 
supply and ischaemia of the affected tissues results. The patient will experience stable 
angina due to coronary ischaemia [57], which may occur at rest or during minimal 
exertion depending on the severity of the occlusion. Prolonged tissue ischaemia may 
also lead to atrophy of the affected tissue, which breaks down and dies by apoptosis. 
This may lead to organ failure, such as renal atrophy in atherosclerotic renal artery 
stenosis.  
        Acute pathologies due to atherosclerotic plaques occur due to plaque erosion or 
rupture, which activates a thrombotic response. The thrombus produced may lead to 
complete or partial vascular obstruction leading to tissue ischaemia [56]. Acute changes 
in plaques are usually more life threatening than chronic low-grade changes. The 
vulnerability of a plaque to rupture is more of a factor in the pathological effect of the 
coronary event, over the extent of the occlusion. Vulnerable plaques are more likely to 
have thin fibrous caps  and larger numbers of foam cells and a large lipid core [56,60]. 
Fewer SMC is a large contributing factor to a vulnerable plaque, as they secrete 
collagen which stabilises the fibrous cap. Low relative numbers of SMC will secrete less 
collagen, causing plaque instability. Clusters of immune cells tips the balance of 
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collagen secretion and degradation towards that of degradation, thus destabilizing the 
mechanical integrity of the plaque. IFN-γ secreted by T-helper cells inhibits collagen 
secretion by SMC, and macrophages secrete various metalloproteinases that degrade 
ECM components. Plaque rupture usually occurs at the point of lesion, where the 
thrombus meets the atheroma. This area is rich in foam cells, suggesting that 
inflammatory factors may influence thrombosis [60].  
       Acute infections also increase risk of myocardial infarction and stroke, due 
inflammatory activation [60]. There are three different forms of clinical disease provoked 
by acute changes to plaques. An acute atherothrombotic occlusion occurs due to 
exposure of the sub-endothelium to the blood stream, leading to activation of the clotting 
cascade and formation of a thrombus. This may cause partial or total occlusion of the 
vessel. Total occlusion of the artery will lead to necrosis of downstream tissues caused 
by irreversible ischaemia, which may be fatal. Atherothrombosis in artery walls may, 
after degradation, result in detachment of small fragments of the thrombus. These then 
embolise in distal sites to the ruptured plaque, causing small infarctions in organs [57]. 
Weakening of the plaque due to inflammatory activity degrading ECM components can 
lead to atherosclerotic aneurysms. An aneurysm is a bulge in the blood vessel caused 
by dilation of the vessel. Sudden rupture of these leads to haemorrhage and high risk of 
fatality [57].  
 
1.6.1.2 Preventative therapies 
Drugs effective at lowering blood cholesterol concentrations and high blood pressure 
are used commonly in the clinic. Statins are the most widely used drug to lower 
cholesterol levels. They act to inhibit the hepatic enzyme responsible for intrinsic 
cholesterol production. This will result in a smaller lipid core beneath fibrous plaques 
and hence a more stable plaque. These are given to patients with 
hypercholesterolaemia and clinical symptoms of coronary heart disease. These 
symptomatic patients may also be taking a combination therapy of statins with aspirin. 
Aspirin is a platelet aggregation inhibitor and hence prevents a thrombotic response to 
plaque injury.  
       More invasive treatments to prevent and reverse cardiovascular disease include 
surgical procedures to remove atheromatous plaques and widen the lumen of the artery. 
Endarterectomy procedures ‘core out’ the fibrous plaque present in the subendothelial 
intima [56]. This dramatically reduces the patient’s risk of acute neurological events. To 
reduce the risk of coronary occlusion events, coronary angioplasty is performed. This is 
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a catheter-based procedure which mechanically widens the lumen of coronary arteries 
obscured by atherosclerotic plaques. This restores blood flow to the heart muscle and 
prevents ischaemia.  This is a very common procedure with high initial success [62]. 
However, later complications such as restenosis may occur where SMC proliferation 
continues due to inflammation at the point of stent insertion [62]. This will eventually re-
form the fibrous plaque over the fatty atheroma and render the surgery useless. The 
materials used in coronary stents must be flexible, supportive, capable of expansion, 
and biocompatible. Typically, foreign materials implanted into the human body results in 
trauma, inflammation, immune response and eventual healing and/or scarring. Materials 
that are not biocompatible can induce many complications, including cytotoxic chemical 
build-up and chronic inflammation. Titanium is the current metal used as a base for 
coronary stent instruments. It is inert and unlikely to evoke an inflammatory reaction. 
 
1.6.1.3 - TiO2 as a novel surface for coronary angioplasty 
Coronary angioplasty, among other invasive procedures, utilises inert surfaces that are 
biocompatible with the human body. However, to avoid an immune reaction to the 
transplanted material, immunosuppressants are commonly used [63]. This reduction in 
the body’s capacity to elicit an inflammatory response often leads to higher occurrences 
of bacterial infection at the site of transplantation [64]. Further to this, titanium medical 
implants are susceptible to microbial colonisation during transplantation [64]. These 
colonies expand within the host to form biofilms – chronic bacterial aggregates enclosed 
within a self-produced polysaccharide matrix [65]. These biofilms are resistant to 
antibiotics and the immune system, causing patients to develop prosthetic joint 
infections [66]. This, along with the induced immunosuppressed state of the patient, 
creates a favourable environment for these microbial aggregates which continue to 
replicate and maintain a state of chronic infection.    
       The number of these preventative procedures is increasing every year due to rising 
obesity and other health problems, and so too is the number of patients developing 
bacterial infections. With the continuous progression of antimicrobial resistance across 
global healthcare practices, there is a growing necessity for effective anti-microbial 
clinical devices. Novel contact-dependent physical approaches are hence being 
developed that aren’t bias towards the killing of non-resistant strains of bacteria, nor do 
they exacerbate the antimicrobial resistance pandemic. Surface architecture and 
topology greatly affect the adherence and proliferative capacity of bacteria on a material 
surface, and hence on biofilm formation too [66]. In a paper by Professor Bo Su, a 
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Professor of biomedical materials at The University of Bristol, he describes the 
development of novel biomaterials with the potential for antimicrobial properties that 
would be suitable for surgical implants. Using a variety of chemical-physical techniques, 
nanostructured titanium (Ti) and titanium dioxide (TiO2) surfaces are generated which 
mimic the surface of many naturally occurring antimicrobials [64]. Taking inspiration from 
nature, nanoscale pillar structures are generated and are composed of TiO2 (Figure 
1.14). These have been previously postulated to promote bacterial surface stretching 
and subsequent rupture between structures in contact with the microbial surface [66]. 
This bactericidal technique is known as contact killing. Using scanning electron 
microscopy (SEM), the morphology of E. coli and K. pneumoniae were observed when 
incubated on Ti and TiO2 treated Ti surfaces. It appeared that the cell thickness was 
markedly reduced when incubated on TiO2 nanostructured surface than when compared 
to the standard Ti flat surface. This was the result of loss of turgor pressure due to 
rupture of the cell membrane, resulting in a collapsed morphology and ultimately cell 
death. Fluorescence microscopy shows an increase in microbial cell death relative to 
cells which are alive when gram negative bacteria are incubated on the nanostructured 
surface.  
       This paper eludes to the antimicrobial effect of nanostructured surfaces for clinically 
applied materials. However, the response of physiological cells to these surfaces is also 
crucial in the efficacy and biocompatibility of the clinical implant. Cells must adhere, 
proliferate and differentiate properly to maintain a state of tissue homeostasis, avoiding 
excess cell proliferation (leading to hyperplasia and possibly tumour growth) and excess 
cell death (necrosis). Therefore, studies that show the response of physiological cells to 



































Figure 1.14 – SEM image of TiO2 nanostructured surface. Ti alloy underwent 
thermal oxidation to obtain randomly oriented TiO2 nanostructures. The scale and 
topology of the nanoscale TiO2 filaments promotes surface stretching and rupture of 
gram-negative bacteria. This contact killing property of the surface may have 
application in the clinic where chronic bacterial infections on clinical implants are 
common. This surface is generated and imaged by Professor Bo Su and colleagues, 
University of Bristol [64]. Scale bar shown = 1µm.	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1.7 Aims & Objectives 
Research into EC biology is in deficit to other well characterised cell types. 
Understanding fundamental endothelial cell biology is necessary to study endothelial 
functions in normal physiology. This study aimed to provide and optimise culture models 
for ECs and apply these techniques to more complex cellular assays. 
Specifically, this study aimed to: 
• Optimise the media used for HUVEC culture by analysing the proliferation of ECs in 
three different commercial formulations.  
• Examine the growth of cells on different bioengineered surfaces, using surfaces with 
potential clinical applications  
• Apply techniques of EC culture to develop a culture of zebrafish ECs  
• Adapt an angiogenic co-culture protocol to a tumour angiogenic co-culture assay  
• Optimise this protocol to gain best density of blood vessels for ease of vascular 
quantification  
• Separately label HUVEC surface membrane proteins in order to detect for specific 
proteins on the apical and basolateral surface through proteomics 
 
In addition to developing and optimising techniques for EC culture, this research project 




CHAPTER 2 Materials and Methods 
2.1 Materials 
2.1.1 Cell culture 
2.1.1.1 Mammalian cell lines 
Cell Type Source 
HUVEC Human Umbilical Vein Endothelial Cells 
Lonza, CC-2519 
 
NHDF Normal Human Dermal Fibroblasts             
Lonza, CC-2511 
SW480  Colorectal adenocarcinoma 
Sourced from ATCC, CCL-228 
SW480 overexpressing VEGF Colorectal adenocarcinoma, stably 
transfected with VEGF by Mr. Haoche 
Wei. 
Sourced from ATCC, CCL-228 
 
2.1.1.2 Zebrafish cells 
Cell Type Source 
Fluorescent transgenic (Tg(fli1a:EGFP) 
zebrafish ECs 
Freshly isolated by Mr. Aaron Scott, 




2.1.1.3 Cell culture media 
Media type Source/composition 
DMEM/F12 Dulbecco’s modified Eagle’s Medium 
Ham’s F-12 nutrient mixture with 3150mg/L 
glucose, 0.55mg/L sodium pyruvate, L-
glutamine and sodium bicarbonate (sigma-
Aldrich D8062) 
EBM-2 Endothelial Cell Basal Medium-2 
Lonza, CC- 3156 
EGM-2 Endothelial Cell Growth Medium-2 
composed of EBM-2 + BulletKit, 
Lonza CC-4176 
FBS Fetal Bovine Solution. Sigma-Aldrich, 
F9665 
Growth medium for SW480 spheroids DMEM with 3150mg/L glucose, 0.55mg/L 
sodium pyruvate, L-glutamine and sodium 
bicarbonate (Sigma-Aldrich D8062)  
Supplemented with 10% (w/v) BSA, 
10µg/ml and 10mg/ml penicillin and 
streptomycin (Sigma-Aldrich P4333) 
Growth medium for transgenic zebrasfish 
ECs 
EGM-2 supplemented with 100µg/ml 




HIFA medium EBM-2 plus Lonza BulletKit™ (CC-3162) 
supplemented with: 
10ng/mL hr FGF/cf, R&D 233-FB-025 
20ng/mL hr IGF/cf, R&D 8335-G1-200 
4µL hydrocortisone (Lonza supplement) 
10µL ascorbic acid (Lonza supplement) 
10µL GA-1000 (gentamicin sulphate-
Amphotericin, Lonza supplement)  
 
2.1.1.4 Cell culture reagents 
Reagent Supplier 
Fibronectin (FN) (0.1%) Sigma-Aldrich, F0895 
Gelatine (2%) Sigma-Aldrich, G1393 
Bovine type I Collagen (2.9mg/ml) Sigma-Aldrich, 5074 
Trypsin-EDTA (0.05%) Thermo Fisher, 252-000-56 
Trypsin neutralising media Lonza, CC-5002 
 
2.1.2 General solutions and buffers 
Solution/buffer Components 
10x Phosphate-buffered saline (PBS) 27mM KCL, 1.4M NaCl, 15mM KH₂PO₄, 
80nM Na₂HPO₄, pH 7.4. 




2.1.3 Immunofluorescence  
2.1.3.1 Reagents 
Reagent Supplier 
4`, 6-diamidino-2-phenylindole (DAPI) Life technologies, D21490 
1, 4-diazabicyclo[2.2.2]octane (DABCO) Sigma-Aldrich, D2522 
Mowiol 4-88 Calbiochem, 475904 
Solution of Mowiol made up to compose of 
2.5% (0.017g) 1,4-diazobicyclo-[2.2.2]-
octane (DABCO, Sigma-Aldrich, D2522) 
with Mowiol, 4-88 (500µl)  
Triton X-100 (0.2%) Sigma-Aldrich, X100 
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Sodium borohydride Sigma-Aldrich, 452882 




2.1.3.2 Primary antibodies 
Target Type Application/dilution Supplier 




WB- 1: 1000 
 
 











WB- 1: 1000 
 
 
IF- 1: 200 
 








Integrin α5  Mouse mAb IF- 1: 200 BD Biosciences, 
743109  
VEGF Mouse mAb IF- 1: 200 R&D systems, 
MAB293 
PECAM-1 Mouse mAb IF- 1: 200 R&D, BBA7 
α-tubulin Mouse mAb WB- 1:5000 Sigma-Aldrich, 
T9026 
VE-cadherin Rabbit pAb IF- 1: 200 Abcam, ab33168 
CD63 Mouse mAb IF- 1: 200 Bio-Rad, MCA2142 

















P-Glycoprotein Mouse mAb IF- 1: 200 Abcam, ab10333 
ICAM-1 Mouse mAb IF- 1: 200 Abcam, ab2213 
Clathrin Heavy 
Chain 
Mouse mAb IF- 1: 200 BD Transduction 
Laboratories, 
610383 
Robo 4 Mouse mAb IF- 1: 200 R&D, MAB2454 
Flotillin 2 Rabbit pAb IF- 1: 200 Abcam, ab96507 







2.1.3.3 Secondary antibodies 
Target Conjugation Host species Dilution Supplier 
Mouse IgG HRP Horse 1: 10,000 Cell signalling 
technology, 
7076 
Rabbit IgG HRP Goat 1: 10,000 Cell signalling 
technology, 
7074 
Mouse IgG Alexa Fluor 488 Goat 1: 10,000 Thermo-Fisher, 
A-11001 
Rabbit IgG Alexa Fluor 488 Goat 1: 10,000 Thermo-Fisher, 
A-11008 
Mouse IgG Alexa Fluor 594 Goat 1: 10,000 Thermo-Fisher, 
A-11005 
Rabbit IgG Alexa Fluor 594 Goat 1: 10,000 Thermo-Fisher, 
A-11012 
Goat IgG Alexa Fluor 594 Donkey 1: 10,000 Thermo-Fisher, 
A-11058 
Mouse IgG Alkaline 
phosphatase 
Rabbit 1: 10,000 Sigma-Aldrich, 
A1902 
 
2.1.3.4 Fluorescent reagents 
Alexa Fluor™ 488 and 594 labelled phalloidin was used at a dilution of 1:400 in BSA. 
Green and red CellTracker™ used from a stock solution made by 1,000x dilution of 
CellTracker™ in DMSO. All reagents bought from Molecular Probes (Life technologies). 
 
2.1.4 ELISA  
2.1.4.1 Reagents 
Reagent Source 
Mouse anti-human VEGF capture antibody R&D Systems, DY293B-05 (1.00 µg/mL) 
Biotinylated goat anti-human VEGF 
detection antibody 
R&D Systems, DY293B-05 (100 ng/mL) 
Streptavidin-HRP R&D Systems, DY293B-05 (40-fold 
dilution) 
Recombinant human VEGF standard R&D Systems, DY293B-05 (2000 pg/mL) 
Wash buffer 0.05% Tween® 20 (Sigma-Aldrich P1379) 
in PBS, PH 7.2-7.4 




O-phenylenediamine (OPD) Sigma-Aldrich, P8287 
 
Citrate phosphate buffer 0.1M citric acid, 0.1M Na₂HPO₄; pH 5.0 
 
 
2.1.5 Immunohistochemistry  
2.1.5.1 Reagents 
Reagent Supplier 
0.3% (v/v) hydrogen peroxide 
Sigma-Aldrich, H1009 
 




2.1.6.1 Biotinylating solutions 
Solution Components 
1x Tris-buffered saline (TBS) Tris buffer (25mM) 
NaCl (0.15M) 
pH 7.2 
Biotinylating solution 200mg/ml EZ-link sulfo-NHS-LC-biotin, 
Thermo Fisher, 21355 
Lysis solution NaCl (137mM) 
Tris buffer (20mM)   
EDTA (1mM) 
NP40 (0.5%) 
1% (w/v) SDS  
DTT  
1x protease inhibitor tablet 
pH 7.5 
3x Laemmli sample buffer 186mM Tris-HCl  
30% (v/v) glycerol 
6% (w/v) SDS  
1% (w/v) bromophenol blue 









Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, 1233508 
Streptavidin beads Thermo-Fisher, 11205D 
 
 
5.1.7 Western blotting 
5.1.7.1 Solutions  
Solution/Buffer Components 
10x SDS-PAGE running buffer 192mM glycine 
25mM Tris base 
1.0% (w/v) SDS 
1x Transfer buffer (high molecular weight) 192mM glycine 
25mM Tris base 
1x Transfer buffer (low molecular weight) 192mM glycine 
25mM Tris base 
10% (m/v) methanol 
Blocking solution 5% (w/v) dry skimmed milk 
1x TBS-T 
10x TBS-Tween 10x TBS 
0.1% Tween 20  
 
2x Laemmli sample buffer 250mM Tris-HCL pH 6.8 
2% (w/v) SDS 
10% (v/v) glycerol 




5.1.7.2 Reagents  
Reagent Supplier 
Acrylamide:bisacrylamide (37.5:1, 30% 
(w/v) acrylamide 
Bio-Rad, 161-0158 
1M Tris-Cl, pH 8.8/6.8 Sigma-Aldrich, T1503 
10% SDS Fischer Scientific, 205-788-1 




Immobilon-P polyvinyl fluoride (PVDF) 
membrane 
Millipore, IPVH00010 
Amersham Hyperfilm GE Healthcare, 28-9068-44 
Amersham ECL western blotting detection 
reagents 
GE Healthcare, RPN2232 






2.2 Methods  
2.2.1 Cell culture 
All mammalian cells were incubated at 37°C in 5% (v/v) CO2.  
2.2.1.1 Coating of plastic culture dishes and plates 
50µg/mL fibronectin in PBS was used to coat each well of a 6, 12 or 24-well plate and 
10µg/mL in PBS used to coat a 10cm dish. Plates and dishes were left for 30 min at 
room temperature prior to the plating of ECs.  
2.2.1.2 Coating of glass coverslips and titanium surfaces 
To acid-washed 13mm coverslips or Ti and TiO2 discs, 50µg/ml fibronectin, 30µg/ml 
type I collagen and 0.1% gelatine (triple coat) in PBS was added and all were incubated 
for 1 h at 37°C.  For a single coat composed only of fibronectin, an aliquot of 500µg/ml 
fibronectin in PBS was added to the surface. ECs were seeded onto the coverslips after 
three washes with PBS.  
2.2.1.3 Coating of Transwell 
Prior to plating of HUVEC, the inside of Transwell with 0.4µm polyester pores were 
coated with 2.5µg/ml fibronectin, 2.5µg/ml gelatine and 50ng/ml collagen for at least 1 h 
at 37°C. The wells were then washed three times with PBS before seeding the 
HUVECs.  
2.2.1.4 Culture of endothelial cells 
HUVEC were cultured in EGM-2 solution in 10 cm dishes until a confluency of ~90% 
was reached. After aspirating the media, the HUVEC were washed twice with PBS 
before an aliquot of trypsin-EDTA (0.5ml for 6cm dish, 1ml for 10cm dish) was added. 
Incubation time at 37°C was dependent on how long it took for cell detachment; 
normally <2 min. 4x volume of trypsin aliquot of neutralising media composed of 
DMEM/F-12 with GA-1000 and 10% FBS was added to the dishes to inactivate the 
trypsin. The cells were counted using a haemocytometer and centrifuged at 1500rpm for 
3 min. The pellet was resuspended in 4ml EGM-2 media. HUVEC were generally 






2.2.1.5 Culture of SW480 cells 
SW480 were cultured in 10cm dishes DMEM/F12 solution until confluent. After 
aspirating the media, the SW480 were washed twice with PBS before a 500µl aliquot of 
trypsin/EDTA was added. The SW480 cells were incubated at 37°C until detached from 
the surface and then 4ml neutralising media added.  
2.2.1.6 Culture of NHDF cells 
NHDF cells were cultured in 10 cm dishes in DMEM/F12 until they reached 80-90% 
confluence (about 7 days). Media was refreshed every 48 h during this period. Cells 
were then passaged by aspirating the culture media, washing twice with PBS and 
addition of 1 ml trypsin-EDTA. Incubation allowed cells to detach from the plastic dish, 
and then cells were harvested in 4 ml DMEM/F12 culture media. NHDF generally 
passaged at a ratio of 1:5. 
2.2.1.7 Isolation of zebrafish endothelial cells 
20x pooled transgenic zebrafish larvae (3 dpf) were dissociated in 500 µl digestion 
buffer (described below) for 1 hour and 23 minutes in a Thermomixer set to 32 ⁰C and 
800 rotations per minute. 500 µl stopping buffer (described below) was added and 
mixed by pipetting. Samples were then centrifuged at 300 g with the supernatant being 
removed and the cell pellet resuspended in suspension medium (described below) – 
this was repeated to wash the cells. This solution was then passed through a 40 µm 
sterile filter before being centrifuged at 300 g and resuspended in 300 µl suspension 
medium and taken for FACS. 
• Perfusion Buffer consists of 1X PBS plus 10 mM HEPES, 30 mM taurine and 
5.5 mM glucose and was stored for up to three months at 4 ⁰C. 49 
•  Digestion Buffer consists of perfusion buffer plus 0.25% Trypsin, 12.5 µM 
CaCl2 and 5 mg/ml Collagenase II and was freshly prepared on the morning of 
the experiment.  
•  Stopping Buffer consists of perfusion buffer plus 10% (vol/vol) FBS and 12.5 
µM CaCl2 and was freshly prepared on the morning of the experiment. 
• Suspension Medium consists of Leibovitz medium L-15 w/0.3mM glutamine 





2.2.1.8 Culture of zebrafish endothelial cells 
Zebrafish ECs were cultured in Lonza EGM-2 media supplemented with 100µg/ml 
Normocin at 28°C in 5% (v/v) CO2.  
 
2.2.2 Proliferation Assay 
HUVEC were seeded on coated 12-well plates at 3x104 cells/mL in freshly aliquoted 
PromoCell EGM-2 media. After cells had attached, the media was replaced with Lonza 
EGM-2 media, PromoCell EGM medium, or an aliquot of PromoCell EGM-2 medium 
that had been made and used before these experiments in the lab. HUVEC were 
harvested as described on section 2.2.1.4 and counted using a haemocytometer at 24, 
48, 72, 96 and 118h after plating. Media was refreshed every 48h.  
 
2.2.3 Immunofluorescence microscopy 
Prior to immunofluorescence microscopy of cells, cells were fixed and stained with 
appropriate reagents. The confocal microscope used was a Leica SP5-AOBS. All 
images using a frame average of 4 and either 5x, 40x or 63x lens.  
 
 
2.2.3.1 Preparing cells for immunofluorescence microscopy 
To fix the cells, 4% paraformaldehyde was added and left to incubate for 15 min at room 
temperature to cross-link proteins within the cells. The cells were washed thrice with 
PBS and permeabilised with 0.2% (w/v) Triton X-100 in PBS for 5 min, before being 
washed with PBS three times. A further 5 min incubation was carried out with 0.1% 
(w/v) sodium borohydride. Cultures were washed thrice with PBS before an aliquot of 
primary antibody, diluted in 1% BSA, or phalloidin, diluted in PBS, was added to the 
cells for 1 h at room temperature. The cells were washed thrice in PBS before an aliquot 
of diluted secondary antibody was added (diluted in PBS) and incubated for 45 min in 
the dark at room temperature. After a 3x PBS wash was carried out to remove the 
secondary antibody, a 1:10,000 dilution of 1mg/ml DAPI was added and left for 45 min. 
Four PBS washes were done before the coverslips or other cell culture surfaces 
(titanium discs and Transwell membranes) were individually transferred to prepared 
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microscope slides. Excess PBS removed by blotting on clean paper towels. 10µl Mowiol 
mounting media was added to the cell culture surface and a 13mm coverslip placed top. 
An overnight period at room temperature was necessary for the Mowiol to set, after this 
the slides were kept in the dark at 4°C. 
 
2.2.4 In vitro tumour angiogenesis co-culture assay 
2.2.4.1 Preparation of methylcellulose solution 
1.2g methylcellulose was added to 50ml of preheated (60°C) DMEM/F12 medium and 
placed on a magnetic stirrer for 20 min. 50ml of DMEM/F12 at 4°C was added to this 
solution which was mixed for a further 1-2 h at 4°C.  
2.2.4.2 Formation and plating of SW480 spheroids 
The DMEM/F12 solution was aspirated from the SW480 cell culture and the 10cm dish 
washed with PBS before trypsin-EDTA added. After <3 min incubation at 37°C 4ml 
neutralizing medium was added and the cells were distributed at [N° spheroids+10] 
*1000 into a 50ml polypropylene tube. Cells were suspended in [N° spheroids+10] *30µl 
methylcellulose stock solution. This was seeded in drops of 30µl onto the lid of an 
inverted tissue culture dish filled with 20ml PBS before being incubated at 37°C for 
around 6 days. Collection of the spheroids required the lid being flushed with 2ml PBS 
and capture of the spheroids into a microfuge tube. Spheroids were collected by 
centrifugation at 1200 rpm for 90 seconds and carefully removal of the supernatant. The 
cells were then resuspended in a solution of 30µl Matrigel and 70µl EGM-2 before being 
plated onto the co-culture. A 15 min incubation at 37°C was carried out before 400µl 
EGM-2 media was added and co-culture was left for 48 h at 37°C. At this point, the 
EGM-2 was refreshed and the plate incubated for a further 48 h before being fixed and 
stained. 
2.2.4.3 In vitro co-culture of NHDF and HUVEC  
NHDF were plated into 12-well plates in EGM-2 at 3x104 cells/ml. Cells were incubated 
at 37°C/5% CO₂ for up to 7 days or until they had reached ~90% confluence. Media was 
refreshed every 48 h. HUVEC in 10cm dishes were cultured as normal (section 2.2.1.4), 





2.2.4.4 Immunohistochemistry co-cultures for quantification  
Immunohistochemistry was carried out to visualise the blood vessel formation in the in 
vitro tumour angiogenesis assay. The co-cultures were fixed using 4% PFA at 4° for 30 
min. The wells were washed with formalin and further fixed in 4% PFA. The plate was 
kept at 4°C for 2 h before being washed twice with PBS. Each well was then incubated 
with 0.3% (v/v) hydrogen peroxide in methanol for 15 min at room temperature. Cells 
were washed 3 times with PBS before a 1 h incubation at 37°C with mouse anti-
PECAM1 primary antibody diluted 1: 1,000 in 1% (w/v) BSA. An incubation with rabbit 
anti-mouse alkaline phosphatase-conjugated secondary antibody diluted 1:500 in 1% 
BSA for 1 h at 37°C was carried out after the primary antibody was removed and cells 
were washed four times with PBS. A six-time repeated wash with water was done 
immediately before freshly prepared BCIP/NBT substrate was added. BCIP/NBT was 
prepared by dissolving 1 tablet in 10ml ddH2O and filtering through a 0.2µm pore filter. A 
30 min incubation at 37°C was carried out to allow for adequate stain to develop. The 
wells were washed four times with ddH2O and then stored at 4°C until imaging. Co-
cultures were imaged by brightfield microscopy using a CCD camera attached to an 
Olympus CKX31 inverted microscope.  
 
2.2.5 ELISA 
A Quantikine Human VEGF Immunoassay kit was used to measure VEGF 
concentration in cell culture medium. All reagents used were warmed to room 
temperature prior to use and were reconstituted according to instructions as given by 
the manufacturer; R&D systems. A working concentration of 1 µg/mL was made of the 
capture antibody by diluting the contents of the vial in 1x PBS. 100µL of the stock 
solution was added to a 96-well plate. An air-tight seal was applied to the plate to 
prevent the evaporation of the antibody before being transferred to 4°C and left 
overnight. The capture antibody solution was aspirated before washing the plate 3 times 
with washing buffer (0.05% Tween-20 in PBS, pH 7.2-7.4). Washing buffer was 
removed at each stage by blotting the plate onto paper towels. Blocking the non-specific 
binding of detection antibody is crucial to get an accurate readout of VEGF levels, 
hence 300µl blocking buffer was added to each well (1% fatty acid free BSA in PBS pH 
7.2-7.4, filtered) which was left to incubate at room temperature for 1 h. A further round 
of aspirating the solution followed by washing three times with washing buffer was 
completed. 100µL of the standard or sample solution was aliquoted into each well, the 
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standard being in appropriate dilutions to create a 7-point standard curve (2-fold dilution 
using blocking buffer starting at 2000pg/mL). The plate was sealed with an adhesive 
strip and left to incubate for 2 h at room temperature. Once its incubation was complete, 
the wells were aspirated and washed with washing buffer three times. A 100µL aliquot 
of the detection antibody was added to each well after dilution to its working 
concentration (100ng/mL). These plates were sealed again and left at room temperature 
for 2 h. The antibody solution was aspirated and washed three times with washing 
buffer post incubation. 100µL of a 40x dilution of streptavidin-HRP was added to each 
well and then the plate was covered and left at room temperature for 20 min, avoiding 
exposure to direct sunlight. The solution was aspirated and washed three times with 
washing buffer before 100µL of substrate solution was added. OPD was used as a 
water-soluble substrate for HRP, producing a yellow-orange colour detectable at 
492nm. After 0.012% (v/v) hydrogen peroxide was added to 50mM citrate phosphate 
buffer (50nM citric acid, 100mM Na₂HPO₄; pH 5.0) OPD (0.8 mg/ml) was dissolved into 
the solution only immediately before adding to the wells. 100µl of this substrate solution 
was added to the wells, which were then incubated for 20 min in the dark, or until a 
yellow colour is seen. 50µl of the stopping solution, 2M H₂SO₄, was added to each well. 
Absorbance of each well was then measured at 492nm.  
 
2.2.6 Immunoprecipitation 
2.2.6.1 Biotinylation of HUVEC on Transwell 
Prior to the addition of biotinylating reagent, 1x105 HUVECs were seeded with EGM-2 
onto Transwell coated with fibronectin, collagen and gelatine (see 2.2.1.3). 2.4x the 
volume of EGM-2 that was added to the top Transwell compartment was added to the 
compartment. After a 24 h incubation at 37°C, the Transwell were washed thrice with 
HIFA medium before 500µl HIFA was added to the inside of the wells and 1.3ml added 
to the outside. Cultures were incubated at 37°C for 48 h to reach confluency. If EDTA 
treated, 1mM EDTA was added to the apical surface of the cells, which were incubated 
at 37°C/5% CO₂ for 5 min. 5mg/mL sulfo-NHS-LC-biotin in HIFA was added to the 






2.2.6.2 Streptavidin immunoprecipitation 
Biotinylated proteins were isolated using streptavidin coupled beads. Following their 
labelling, HUVEC were washed twice with TBS to remove excess biotinylation reagent. 
Lysis solution was added to the apical surface of the cells in the Transwells for 2 min. 
The cells were harvested by using a pipette to scrape and transfer lysate to microfuge 
tubes. If multiple wells were being used for one sample, lysis solution was transferred 
between wells before collection into microfuge tubes. Final aliquots were collected and 
kept on ice for 30 min. microfuge tubes were centrifuged at 4°C and 15000 x g for 12 
min and supernatant containing the solubilized proteins collected and kept on ice.  
       Before use, streptavidin beads were pelleted via a three-time wash in lysis buffer 
and centrifugation at 1000 x g for 3 min at 4°C. Bead pellets were added to the sample 
solutions. These were then kept at 4°C with gentle agitation for 1 h before centrifugation 
at 1000 x g and 4°C for 3 min, discarding the supernatant. The samples were then 
washed again three times with lysis buffer with centrifugation at 1000 x g at 4°C for 3 
min to remove non-biotinylated proteins. 3x Laemmli Sample buffer with 325mM DTT 
was added to the samples and the solutions left for 5 min at 95°C before being stored at 
-20°. Samples could then be analysed by SDS-PAGE and western blotting. 
 
2.2.7 Sodium-dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were analysed using SDS-PAGE and western blotting. After IP, 2x Laemmli 
sample buffer was loaded in equal volume to the samples, which allowed proteins in the 
sample to become reduced and denatured when heated to 95°C, which were then ran 
on hand-cast gels. A 10% separating gel was generally used, prepared using 10% (w/v) 
acrylamide/0.3% (w/v) bis-acrylamide, 0.1% SDS and 0.38M Tris-Cl (pH 8.8), 0.1% 
(w/v) ammonium persulphate (APS). The acrylamide could polymerise when 0.1% (v/v) 
TEMED was added just before pouring. Once set and levelled using 0.01% (w/v) SDS 
overlaid on top of the gel, stacking gel was prepared using 3.9% (w/v) acrylamide/0.1% 
bis-acrylamide, 0.1% SDS, 0.125M Tris-Cl (pH 6.8) and 0.05% APS. 0.1% TEMED was 
added just before pouring on top of the separating gel to allow polymerisation of the 
acrylamide. Once solidified, the wells were washed with 1x SDS-PAGE running buffer 
and the protein marker and samples were added. The cell was loaded with the gel and 
1x SDS-PAGE running buffer and ran at 20mA for 20 min until the samples entered the 




2.2.8 Western blotting 
After their separation by SDS-PAGE electrophoresis, the protein samples on the gel 
were transferred onto an Immobilon-P polyvinyl fluoride (PVDF) membrane to allow their 
detection using antibodies or other high affinity binding methods. The gel was placed 
onto an activated PVDF membrane and this was then sandwiched between filter paper 
and fibre pads, both soaked in Western Transfer Buffer (WTB). The cassettes were 
loaded into Bio-Rad Mini Trans-Blot electrophoretic transfer cells which were filled with 
WTB, and proteins allowed to transfer at 270mA for 1 h at 4°C.  
       The transfer membrane was moved to a 5% (w/v) solution of dry skimmed milk 
powder diluted in PBS-Tween to prevent unspecific binding of primary antibody. After 
this the membrane was washed with 1xTBS-Tween and then incubated with primary 
antibody diluted in 1x TBS-Tween overnight at 4°C with gentle agitation. Excess 
antibody was removed by a three-time wash in TBS-Tween before the secondary-HRP 
antibody (diluted in TBS-Tween) was added for 1 h at room temperature. The 
membrane was again washed thrice with TBS-Tween prior to detection of the secondary 
antibody. Excess TBS-Tween was removed, and the membrane was soaked in 
enhanced chemiluminescence (ECL) detection reagents in a 1:1 mixture. The soaked 
membrane was covered in clingfilm and exposed to Hyperfilm for an amount of time 














Chapter 3 Endothelial cell proliferation assays 
3.1 Introduction 
To study endothelial biology, it is useful to be able to culture ECs in vitro. Culturing ECs 
allows examination of their normal functions, but also allows for the study of pathological 
conditions. HUVECs are routinely used as model ECs and are prepared from the major 
vein of human umbilical cords. The main advantage from using this source is that the 
cells are easy to obtain, and as they are primary cells, they retain most of the properties 
of normal ECs far better than a cell line. Retaining their morphologically and 
physiologically unique properties is important for generating a cell culture that behaves 
in a biochemically similar way as an in vivo scenario. A major negative however, is that 
they have a limited life in culture before the cells begin to lose their distinct properties. 
The aim of the work in this first chapter was to learn the basic techniques of EC culture. 
While doing this, I also aimed to optimise and develop these techniques.  
This work had three objectives: 
1) To optimise the media used for HUVEC culture by analysing the proliferation 
of ECs in three different commercial formulations. 
2) To examine the growth of cells on different bioengineered surfaces, using 
surfaces with potential clinical applications 
3) To apply techniques of EC culture to develop a culture of zebrafish ECs 
The number of, and reliance on, clinical applications based around in vitro models for 
angiogenesis is increasing and so it is growing more and more important to generate 
EC culture models.  
 
3.2 Results 
3.2.1 Optimisation of HUVEC culture 
There are several different commercial sources of EC growth media. The lab usually 
uses Lonza EGM-2 as its primary EC culture formulation. There have been, however, 
recent problems with the supply of this media. The lab has since substituted Lonza 
EGM-2 with PromoCell EGM-2. However, HUVECs cultured in this media have recently 
had low proliferative rates. To assess possible alternatives, I analysed the proliferation 
of HUVEC in four different culture media. To do this, I calculated the number of cells 
present in each culture every 24h and observed trends in their growth. All three media 
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are composed of endothelial basal medium with additional supplements. The Lonza 
EGM-2 medium usually used by the lab contains the same supplements as the 
PromoCell EGM-2 medium, although these probably differ slightly in concentration. 
These supplements are refined, purified biochemical agents whose concentrations and 
activities will remain constant in every aliquot. PromoCell EGM, on the other hand, 
contains bovine pituitary extract, which contains crude versions of these components 
whose concentrations and activities will range depending on the aliquot. It will also 
contain undefined proteins present in the pituitary sample used, including bovine serum 
albumin (BSA). Two separate PromoCell EGM-2 were investigated; an aliquot of 
previously prepared EGM-2 that had caused low HUVEC proliferation (old PromoCell 
EGM-2), and an aliquot that was freshly prepared. This experiment seeded 3x104 
cells/mL into plates which were then cultured in each of the three different media. Every 
24h the concentration of cells grown under the three different media was calculated. 
The rates of cell growth gave an indication of the best-suited media to HUVEC cell 
culture.  
       As shown in Figure 3.1, HUVEC cultured with Lonza EGM-2 media had greater 
proliferation than when using PromoCell EGM media (****p ≤ 0.0001). This is to be 
expected, as EGM-2 culture media contain refined growth components whose 
concentrations reflect the requirements of HUVEC. EGM, however, contains crude 
components whose concentrations will not have been optimised for HUVEC growth and 
proliferation. Lonza EGM-2 media also gave greater proliferation than the freshly 
prepared PromoCell EGM-2 media (***p ≤ 0.001). An anomaly occurred when HUVEC 
were cultured with an aliquot of PromoCell EGM-2 which had been suspended before 
this experiment. These HUVECs displayed no cell proliferation, and the number of cells 
declines within 24h after plating. By 72h there are no HUVEC surviving when incubated 
with this supply of PromoCell EGM-2 medium. It is likely that this supply of PromoCell 
EGM-2 did not contain all the growth components, or proper concentrations of these 
components, to support HUVEC growth and proliferation. HUVECs cultured in all four 
media show a likely decline in cell number at day 5. Thus, the optimal incubatory period 
is 4 days post seeding, after which the amount of growth components contained in the 
growth media begin to fall below that needed for cell survival and proliferation. HUVEC 
cultured with Lonza EGM-2 generally had the greatest observed cell proliferation at day 
4 (max proliferation) and so this is the growth medium which should be used in all 





























Figure 3.1 – Proliferation and survival of HUVEC differs when cultured in 
different culture media. ECs were seeded on coated 24-well plates at a 
concentration of 3x104 cells/mL and cultured with Lonza EGM-2 (control) or 
PromoCell EGM, or with old or freshly aliquoted PromoCell EGM-2 media. 
Proliferation was analysed by counting fixed cells at 24, 48, 72, 96 and 118h after 
plating (days 1-5). Data shows the mean ± SEM of three experimental replicates. 
Statistical analysis was performed using a two-way ANOVA on all the data followed 
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3.2.2 Confluency of HUVEC differs on different bioengineered surfaces 
In cell culture, HUVECs are normally grown on either glass or plastic surfaces. In 
surgical implants such as stents that are placed in the coronary arteries of patients with 
atherosclerosis, the surface used is titanium (Ti). These biochemical surfaces need to 
be inert and anti-microbial so that they do not provoke an immune reaction and must 
also support the adherence and proliferation of the patient’s ECs, which should ideally 
grow to cover the surface. Professor Bo Su, who works on the development of surfaces 
for biomedical applications, proposed titanium dioxide (TiO2) as a potential surface for 
stenting [67]. This surface has a nanostructured architecture composed of filamentous 
protrusions with diameters of <50nm that repress the growth of bacteria by contact-
dependent fission of bacterial surface membranes resulting in cell lysis and death [67]. 
The micro-structure has also been shown to increase the adherence and differentiation 
of physiological cells cultured on its surface by increasing the number of focal adhesion 
domains [68]. Specifically, it increases the number of phosphorylated focal adhesion 
kinase (pFAK) loci [68]. When phosphorylated, this kinase becomes activated and will 
initiate downstream signalling events promoting cell proliferation, survival, migration, 
invasion and angiogenesis.  
       I set out to study the culture of HUVEC on TiO2 to ascertain the possibility of 
application of TiO2 within this field. I used Ti and glass surfaces as controls, Ti not being 
modified by chemicophysical means and so representing a non-modified version of the 
TiO2 surface that has a flat surface topology. It is also the surface currently used in 
prosthetic implant procedures in clinic. Glass is a good surface for HUVEC culture and 
is routinely used in the lab in cell culture assays. It was used to compare the efficacy of 
the TiO2 and Ti surfaces for HUVEC culture. I seeded the HUVEC on the three different 
surfaces and then assessed their visual confluency after culture. Labelling their nuclei 
and actin cytoskeleton with DAPI and phalloidin respectively allowed the cells’ 
confluency to be visualised using fluorescence microscopy.  
      Confluency of the cells was best achieved when HUVEC were cultured on glass 
coverslips (Figure 3.2) and when the surface was coated with fibronectin (FN), gelatine 
and collagen i.e. triple coat. The cell surfaces are in close contact with one another and 
appear as one monolayer. Cells grown on Ti are sparser than those grown on glass, 
with more gaps in the monolayer. Those HUVEC seeded onto TiO2 formed islands of 
cells with gaps separating them from each other. The cells do not form a continuous 
monolayer with consistent cell-cell contacts and less cell spreading is observed. 
Furthermore, the control group where no coat was applied to the surface gave the least 
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confluent monolayer of HUVEC compared to the two coated surfaces. FN coating the 
surfaces allowed for somewhat confluent EC growth. 
 
3.2.2.1 HUVEC cultured on TiO2 surfaces exhibit markers of genetic 
instability	  
Whilst undergoing fluorescence microscopy analysis of the HUVEC grown on the three 
different biomaterials, markers for genetic instability were uncovered. Irregularities with 
the DAPI stained nuclei were seen. Some such irregularities were small pieces of DNA 
external to the main body of genetic information. There were additional thin bridges of 
DNA stretching from one nuclei to another across two separate cells. After inspection, 
these irregularities were determined to be micro-nuclei and chromatin bridges 
respectively (Figure 3.3). Both are caused by malfunctions in cellular division. Micro-
nuclei are whole or fragmented chromosomes that fail to be incorporated into the nuclei 
of a daughter cell during cell division. Chromatin bridges are the result of end-end 
fusions of homologous chromosomes during metaphase, which fail to be resolved 
before interphase of the following cell cycle. Such features usually result in genetic 
alterations as the two daughter cells receive asymmetric genomes. 
       HUVEC cultured on the TiO2 surface generally showed relatively more markers for 
genetic instability (Figure 3.4). HUVEC cultured on FN coated TiO2, as well as HUVEC 
cultured on control TiO2 , showed relatively greater amounts of micro-nuclei compared 
with corresponding coatings on glass or Ti (Figure 3.4a). However, HUVEC cultured on 
triple coated Ti showed a relatively greater percentage of micro-nuclei than HUVEC 
cultured on glass or Ti surface, and triple coated TiO₂. 
       In addition, TiO2 generally gave a much greater percentage of chromatin bridges 
than the other two surfaces. As shown in Figure 3.4b, all three coated surfaces 
generated a higher percentage of chromatin bridges than any of the coatings on the 
other two surfaces. Aside from triple coated Ti, no chromatin bridges were observed in 
HUVEC cultured on glass and Ti surfaces.   
       The results acquired from this experiment cast doubt on the utility of TiO2 as a 
surface for coronary angioplasty stenting, or indeed any other medical procedure where 
TiO2 is used as a surface for cell growth. Because of this, I abandoned further research 








































Figure 3.2 – Confluency of HUVEC depends on the surface and underlying 
substratum. HUVEC stained with DAPI and phalloidin to give visual indication of 
confluency and health of the cells. HUVEC were seeded on glass coverslips at a 
concentration of 6x104 cells/mL and on Ti and TiO2 surfaces at concentration of 
2.6x10
5 
cells/mL before being cultured for 48h and then fixed and stained. (a) 
HUVEC seeded on glass coverslips developed into a confluent monolayer with 
cellular attachments. (b) HUVEC seeded on Ti surface gave moderately confluent 
monolayer of cells, however cellular junctions do not appear to have formed. (c) 
HUVEC seeded onto TiO2 had a relatively low confluency, forming islands of cells 
rather than one continuous monolayer. (i) Control to compare the effect of using 
ECM components to coat the biomaterials. When no coat is applied, the cells 
struggle to form confluency. (ii) FN coated surfaces aid in allowing confluency, 
however the effect is greater with triple coated (FN, gelatine and collagen) surfaces 























Figure 3.3 – HUVEC grown on TiO
2
 display a greater number of micro-nuclei and 
chromatin bridges. HUVEC seeded onto TiO
2
 biomaterial at 2x10⁵ cells/mL were 
fixed and DAPI stained after 48h. Confocal microscopy images reveal DNA that is 
surrounded by a nuclear envelope but external to the main body of nuclear material 
(micro-nuclei) and genetic linkages between two daughter cells exiting mitosis 
(chromatin bridges). The image taken above is from HUVEC cultured on FN coated 
TiO₂. Figure shows RGB channel for original image displaying both micronucleus and 
chromatin bridge. Also shown is single channel (blue) for both features, which have 

































	   	  
	  
Figure 3.4 – Disparity of two genetic instability markers, micro-nuclei and 
chromatin bridges, across three biomaterials and surface coats. The number of 
cells and cells with genetic instability markers were counted on microscope slides 
using a widefield microscope. % micro-nuclei and % chromatin bridges were 
calculated using this data. Each surface was coated with either FN or a triple coat of 
FN, gelatine and collagen, or kept uncoated as a control. TiO2 generally generated the 
greatest amount of genetic instability for both markers. Data shows % micro-
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3.2.3 An In vitro model for transgenic zebrafish larvae endothelial cells  
The use of zebrafish as a model organism to understand human disease and physiology 
is increasing. Zebrafish are easier to genetically manipulate, inexpensive and suitable 
for larger scale genetic studies [69]. It is advantageous to use them as a model 
organism over a mammalian organism, such as a rat, as these have ethical, time scale 
and expense deficiencies.  
       Having an in vivo human model would be useful when modelling human physiology 
and disease. However, this is not possible due to ethical restraints. The use of human 
cells is therefore limited to in vitro models. In contrast, there are far fewer ethical 
restraints on making in vivo models using zebrafish. Further to this, their early 
development occurs externally, and zebrafish embryos are nearly transparent. This 
makes it possible to study their internal physiology and anatomy during early 
development using a low magnification microscope. These in vivo models are useful for 
studying processes and structures that occur in their physiological niche. In vitro 
models, however, would complement these as they are high throughput and simpler 
thus providing faster and more robust results that can form the basis of further in vivo 
studies. I therefore wanted to create an in vitro model for zebrafish EC culture. 
Complementing current zebrafish vasculature in vivo models would provide valuable 
information which could have clinical applications.  
       My research is based on the study of ECs taken from human sources. I therefore 
wanted to use this technical knowledge to develop a protocol for the culture of zebrafish 
ECs. To achieve this, I cultured fluorescent transgenic zebrafish larvae ECs that were 
labelled with Tg(fli1a:EGFP) marker on coated plastic plates and stained them with 
DAPI in order to count them. Fli1 is a strong promoter, which belongs to the ETS 
transcription factor family [70]. This family of proteins is critical for the development of 
the vasculature. It is therefore present in ECs across the entire vasculature, hence GFP 
is highly expressed in these cells providing a distinguishable marker for the 
endothelium. These transgenic ECs were obtained from zebrafish larvae at four days 
post fertilisation (dpf), and were cell sorted using fluorescence-activated cell sorting 
technique.   
       In particular, I focussed on the growth rate of zebrafish ECs in culture, and on 
optimising this protocol to obtain a useful concentration of ECs that could be used for 
further experimentation. It is known that HUVECs reach confluency when in cell culture 
medium at around 48h, and so I wanted to investigate whether the same was also true 
in zebrafish ECs. A growth curve experiment was set up to determine an optimum 
incubatory period to reach confluency. As shown in Figure 3.5, the zebrafish EC number 
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grew little if at all up to 48h. After this, the cell number begins to decline. Overall, there 
is no extensive zebrafish EC proliferation that would otherwise be seen in HUVEC cell 
culture.  
       To give visual representation of their confluency, zebrafish ECs were fixed and 
stained with DAPI (Figure 3.6). Preliminary cultures, using a 12-well plate, gave low 
confluency of the ECs (Figure 3.6a-c), the sparsity of the cells meant generally only 
single cells could be imaged. The cells in this experiment had an array of different 
morphologies which look dissimilar to that of normal ECs. ECs are usually elongated 
polygons, predominantly hexagonal. The five cells shown in Figure 3.6a-c possess large 
differences in morphology from one another. Figure 3.6a shows a cell with filamentous 
projections coming out from the main body of the cell, which suggests that it is a 
dendritic cell. Figure 3.6b shows a small, spherical cell with a large nucleus with a 
diameter of about 7-10µm, characteristic of a lymphocyte. The other cell in Figure 3.6b, 
and those in Figure 3.6c, have morphologies that is more characteristic of ECs. One of 
the cells in Figure 3.6c appears to be engulfing another cell or fragment of a cell. This is 
not a characterism of an EC, and so casts doubt regarding the purity of these sorted 
cells. 
       Secondary experiments using a 96-well plate gave higher concentrations of the 
seeded zebrafish ECs, and as a result a greater confluency. Despite achieving greater 
confluency, the zebrafish ECs did not form normal cell-cell junctions. Figure 3.6d+e 
shows that junctions form at regions of the plasma membrane that are relatively spaced 
out from one junction to the next. The main body of the cells are also more condensed 
than that seen characteristically in ECs. This gives a more fibrillar morphology of the 
cells, as region of the plasma membrane that form the cell-cell junctions must stretch 
further away from the cell body to form cellular connections. Despite the relative 
abnormality in the cellular junctions seen in these cells compared to normal ECs, their 
morphology is much more like that of normal ECs. Lastly, the cells grown in 12-well 
plates as shown in Figure 3.6a-c have a relatively greater diameter compared to the 
cells grown in 96-well plates as shown in Figure 3.6d+e. It appears that when zebrafish 


































Figure 3.5 – Growth curve for zebrafish endothelial cells cultured over 
five consecutive days.	   Zebrafish ECs were cultured in a 96-well plate in 
Lonza EGM-2 media supplemented with Normocin and images of ECs were 
taken using a widefield imaging microscope. Fluorescent Tg(fli1a:EGFP) 
marker and DAPI staining allowed visualisation of the cells. Number of cells 
was counted in 3 random fields of view for each day. The number of cells was 
averaged across three measurements. The starting concentration of cells was 
6x10
4


































	  	  	  
Figure 3.6 – Fluorescent transgenic (Tg(fli1a:EGFP) zebrafish sorted from 
whole larvae using FACS and cultured on coated plates. Representative 
confocal images for transgenic zebrafish with GFP driven expression by Fli1 EC 
promoter in as a cytosolic marker for endothelial cells. DAPI staining of nuclei 
carried out after fixation. (a-c) Individual zebrafish ECs in 12-well plate where cells 
lacked confluency. (d+e) ECs cultured in 96-well plate to greater confluency. ECs 








The findings from this set of data successfully determined that the HUVEC culture 
media that allows for the greatest cell proliferation and survival is Lonza EGM-2. This is 
the HUVEC growth medium that is normally used in the lab, whose supply has been 
discontinued. Until it is re-distributed, PromoCell EGM-2 should be used instead, as the 
HUVEC proliferation assay using this media had the second-best growth curve. 
       Once the correct media for proper HUVEC culture was established, further cell 
culture experiments could be carried out. Initially, the work on this chapter was based on 
research carried out by Professor Bo Su and colleagues [63]. They had proposed a 
novel surface for clinical applications that is biocompatible and has bacteriocidal 
properties. This surface, TiO2, has nanopillar patterns which physically burst gram-
negative bacteria that come into direct contact with the surface. Professor Su had 
observed a dramatic decrease in bacterial cell viability when gram negative bacteria 
were cultured on nanopatterned TiO2 surfaces [67]. Further to this, Park et al 
investigated the capability of this surface to support physiological cells [68]. It was found 
that TiO2 nanopillars support, rather than prevent, cell proliferation on their surface when 
nanotubes were spaced between 15-30nm apart. I wanted to determine whether 
HUVEC growth and proliferation could be supported on TiO2 coated surfaces, using 
glass and Ti surfaces as controls. As shown in Figure 3.2, HUVEC achieved the best 
confluency when seeded on glass coverslips, with the worst confluency observed on 
TiO2. Delineating the results from this experiment, it can be said that TiO2 does not 
prevent HUVEC growth on its surface, however neither does it properly support HUVEC 
growth and proliferation. 
       In studying HUVEC culture on different surfaces, it was discovered that TiO2 
generated markers of genetic instability in the HUVECs. Interestingly, HUVEC cultured 
on TiO2 displayed a considerably greater number of micro-nuclei and chromatin bridges, 
as a % of total nuclei, than HUVEC grown on glass and Ti surfaces (Figure 3.4). These 
genetic instability markers within cells have a high chance to manifest as genomic 
alterations, potentially leading to tumourigenesis. This, taken together with data from 
Figure 3.2, casts doubt on the use for TiO2 in clinical applications. Its effect on HUVECs 
cultured on its surface needs to be investigated further to deduce all of its potentially 
hazardous cellular effects before it can be applied in a human.  
       One of the aims of the work in this chapter was to successfully develop a culture of 
zebrafish ECs. To be successful, this would involve the ECs attaching to the surface of 
the culture plate before proliferating and attaining enough cell survival to maintain the 
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culture for a number of days. Results from Figure 3.5 show that, when cultured in EGM-
2 supplemented with Normocin, the transgenic zebrafish larvae ECs were successfully 
seeded, and maintained at a relatively stable concentration for around 48h. Normocin is 
an antimicrobial reagent, active against gram-positive and gram-negative bacteria, as 
well as against fungi. It was added to the EGM-2 cultured zebrafish ECs as initial 
conditions promoted the growth of fungi in the cell culture. Advanced contaminations 
with fungi cause increases in pH in the culture. This, together with competition for 
growth factors and other components required for cell viability and growth, causes a 
decline in cell number in the culture. Despite EGM-2 being supplemented with 
Normocin, the zebrafish EC number dropped after this point, suggesting that the cell 
culture conditions were not optimal for proliferation. Compared to HUVEC cell culture, 
the proliferation of these zebrafish ECs is much lower. EGM-2 is optimised for HUVEC 
cell culture, and so this may not provide the amounts and/or types of growth 
components necessary for rapid zebrafish EC proliferation due to differences in growth 
factor requirements across species. Fetal bovine serum (FBS) could be used to 
supplement the EGM-2 cell culture medium used; EGM-2 media used within the lab 
does not contain any serum, just purified growth factors and cytokines. FBS contains an 
array of crude growth factors and is more versatile for a variety of different cell culture 
applications. Reducing the surface: volume ratio of the culture plate from a 12-well to a 
96-well plate improved the resulting confluency of the ECs and hence this optimised 
protocol has greater application for further experiments. Thus, this is a good starting 
point in producing a zebrafish EC culture protocol, however there is a lot of scope for 
optimisation, especially regarding optimising a culture medium. 
       Additionally, the morphologies of the zebrafish ECs, as shown in Figure 3.6a-c, do 
not conform to usual ECs. This suggests that cells other than ECs were sorted by FACS 
and cultured alongside cells containing the GFP marker. The Fli1 gene is present in all 
hematopoietic cell lineages, as well as in lung, heart and ovary tissue [50]. During site 
specific recombination of the Fli1:GFP construct there may have been incorporation into 
these other cell types. If these cells express GFP, they will be sorted as ECs by FACS 
and be included in the cell culture. Both dendritic cells and lymphocytes are a part of the 
hematopoietic cell lineage and so have the potential to gain the Fli1:GFP construct and 
become fluorescently labelled. A further method of cell sorting would be required to 
obtain a purer culture of zebrafish ECs.  
      Work in this chapter was intended to optimise various endothelial assays, but also to 
allow me to gain training in EC culture. By the end of this primary work, I was confident 
to continue to develop a more complicated assay.  
73	  
	  
Chapter 4 Adaptation of an in vitro angiogenesis assay to study tumour 
angiogenesis 
4.1 Introduction 
The development of several different in vitro co-culture assays has allowed two or more 
different cell types, either primary or cell line derived, to be cultured in concert. This 
level of cellular interaction means that their environment more closely resembles that of 
their physiological niche. The Mellor lab, where I am based, uses a well characterised 
co-culture assay to study angiogenesis [71]. The original assay combines primary 
endothelial cells (HUVECs) together with primary fibroblasts (NHDFs) in a 1:1 ratio 
simultaneously [72]. Over the course of 7-14 days the endothelial cells mature into 
tubules that form a dense network as a direct result of cellular interactions [71]. The 
interaction between these two cell types and that of the endothelial cells with the ECM is 
the driving force for blood vessel development. As occurs in vivo, the fibroblasts 
remodel the ECM into fibrillar collagen to support the tubulation of the ECs [73]. After a 
period of 5-10 days the co-culture will be a dense network of branching ECs – cellular 
branches extend into the X-Y plane and into the Z plane forming layers of capillary-like 
vessels that result in a 3D network [74].  
       My work with the Mellor lab involved the study of tumour angiogenesis. My goal 
was to adapt the co-culture assay used to study angiogenesis into one which 
investigates tumour angiogenesis. This adaptation uses 3D tumour cell spheroids and 
seeds them onto the well characterised co-culture assay once the co-culture becomes 
confluent. The 3D nature of the tumour cell clusters means that the tumour angiogenic 
effect is localised and the cancer cells are in an environment that closely resembles that 
in vivo. This assay can be used to quantitatively and visually assess the angiogenic 
effect of different tumours and hence give some indication of their aggressiveness.  
This work had the following aims: 
1. Form 3D spheroids of SW480 cell lines to recapitulate in vivo tumour 
architecture  
2. Validate an SW480 cell line that has been virally transduced with VEGF  
3. Adapt an angiogenic co-culture protocol to a tumour angiogenic co-culture assay 






4.2.1 SW480 cancer cells can form 3D spheroids when combined with 
methylcellulose 
The cancer cell line chosen was SW480, a colorectal adenocarcinoma line. This line 
was chosen for its growth pattern reproducibility in culture. The growth rate of these 
cells is relatively constant throughout the entire culture, meaning a similar number of 
SW480 cells are in each spheroid and so the angiogenic effect of each type of spheroid 
will be similar. SW480 cells are also at a relatively low stage of epithelial-mesenchymal 
transition and hence still maintain some E-cadherin junctions. In this experiment, some 
cell-cell contact is necessary to form multi-cellular spheroids where cells must directly 
bind one another and the ECM. The tumour stage was therefore picked to match the in 
vitro model.  
       Culturing cell lines in 3D allows for in vivo architectures to be generated, providing a 
platform for complex cellular interactions to occur. Several 3D cell culture protocols exist 
involving either scaffold-based 3D-models or scaffold free models (liquid based) [75]. In 
this experiment, I used scaffold-free systems as this promotes the endogenous 
production of ECM components and hence more closely resembles an in vivo scenario. 
By using the hanging drop method, multi-cellular SW480 aggregates form, mimicking 
their in vivo architecture. These so called spheroids [75] are composed of several 
hundred cancer cells which aggregate into clusters at the apex of a drop of media 
suspended on the lid of a tissue culture dish (Figure 4.1). As shown (Figure 4.1a) the 
SW480 cells form viscous droplets when combined with methylcellulose that can be 
cultured by the hanging-drop method when inverted in a tissue culture dish lid. These 
spheroids vary in size (Figure 4.1b) and become dispersed evenly within the 
methylcellulose. Methylcellulose, a derivative of cellulose, was chosen for its high 
viscosity when dissolved in water, which allows for the localised clumping of the cancer 
cells.  
 
4.2.1.1 Validation of the SW480 V cell line 
Jimmy Wei, a PhD researcher within my lab, created a stable SW480 cell line that 
overexpresses VEGF (SW480 V). High VEGF levels have a close association with high 
blood vessel density at the site of a tumour, and poor disease prognosis. I set out to 

































Figure 4.1. Images of the hanging-drop method for cell culture. (a) 30µl 
droplets of methylcellulose plated onto the lid of a petri dish, each containing 
roughly 1000 SW480 cells. The lid is inverted above 20mL PBS and incubated at 
37°C/5% CO2. (b) Multi-cellular aggregates of SW480 cells present at the apex of a 




the SW480 parental cell line (SW480 P).  In order to do this, I carried out an ELISA to 
quantitatively measure the amount of VEGF in the medium from SW480 V and P cell 
cultures. 
       By first constructing a standard curve, validation of the relationship between 
absorbance and VEGF concentration could be deduced. Using a recombinant standard 
VEGF solution, I found that the curve had a positive correlation, with each point 
following the curve closely (Figure 4.2a). Interestingly, I found that SW480 P secretes 
little or no VEGF (Figure 4.2b). This does not follow the general assumption that tumour 
cells upregulate VEGF production. SW480 V secretes relatively much more VEGF than 
SW480 P, with concentrations in the medium at around 80 pg/mL (P<0.01). The 
average VEGF concentration in peripheral venous plasma, with samples taken from 
2833 patients totally a wide variety of cancer types, is 328 pg/ml [76]. The SW480 cell 
line obtained is likely to have lost some of its tumour properties during passaging and so 
its capacity to express and secrete VEGF will have declined. 
      The average VEGF concentration was calculated for both cell lines (Figure 4.2b). To 
determine how homologous the expression of VEGF was from each cell line, I carried 
out an immunofluorescence protocol. SW480 P had no visible expression of VEGF 
(Figure 4.3a) shown by the lack of green signal that would have been generated by the 
Alexa Fluor® 488-conjugated secondary antibody. Conversely, SW480 V produces 
VEGF in much greater amounts (Figure 4.2+4.3b). The staining shows signal in vesicles 
around the nucleus and in areas beneath the cell. The latter suggests that this VEGF is 
being secreted and subsequently trapped by components of the ECM. Since the VEGF 
signal is relatively evenly dispersed across all the cells, they must all be secreting VEGF 






































Figure 4.2 – Concentration of VEGF secreted from SW480 P and SW480 V 
cells. SW480 V secretes significantly higher amounts of VEGF compared to 
SW480 P when ELISA was performed to quantitatively measure VEGF 
concentration. (a) A two-fold serial dilution of standard VEGF solution was made 
to create a 7-point curve, showing the association between VEGF concentration 
and absorbance at 492nm. (b) Average [VEGF] secreted by SW480 V + P was 
calculated using the standard curve and A492nm values. Samples were taken 
from both cell lines, seeded at concentrations of 1x10
5
 cells/ml for 48 hrs, by 
collection of medium. SW480 V secreted more VEGF than the parental cell line. 
Statistical analysis was performed using a Student’s t-test, **P<0.01. Data are 
means +/- SEM of three experimental replicates. 

























































Figure 4.3 – VEGF immunofluorescence staining of SW480 P and SW480 V 
cells. SW480 P and SW480 V cells were seeded onto coverslips at a concentration 
of 1x10
5
 cells/ml. Cells were exposed to DAPI and anti-human VEGF antibody with 
compatible fluorescently labelled secondary antibody to stain for nuclei and VEGF 
secretions respectively. Cells were imaged by confocal microscopy to visualise their 
locations. (a) SW480 parental cell line shows only DAPI staining. (b) SW480 V 
shows DAPI staining and staining for both vesicular VEGF and VEGF ‘clouds’. 




4.2.2 Adaptation and optimisation of the tumour angiogenesis assay 
As already discussed, there is a well-established protocol for the co-culture of NHDF 
and HUVEC (angiogenesis assay). Here, I am building on the adaptation of this 
protocol, integrating 3D tumour spheroids into the co-culture. This tumour angiogenesis 
assay gave quantitative data as to whether SW480 V promoted angiogenesis, relative to 
SW480 P. There had, however, been difficulties in determining whether there was a 
directionality of the blood vessels that was caused by the SW480 spheroids. The 
density of the blood vessels had to be optimal for the assay for blood vessel 
directionality to be distinguished. They must not be too dense, as there is a high chance 
that the SW480 spheroids would be seeded directly onto vasculature. This would give 
no indication as to whether the blood vessels are responding to the spheroid or not as 
there would be little or no movement away from the spheroid. If the blood vessels are 
too sparse however, they may be at too great a distance away from the spheroids that 
they cannot respond to the VEGF gradient. It would also be hard to tell if the direction 
the blood vessels are growing towards is due to the spheroids, or due to chance alone. 
The density is dependent on the incubation period of the co-culture after HUVEC and 
tumour spheroids have been seeded. I therefore set up a time course experiment 
whereby the incubation times for these two events in the co-culture differed, resulting in 
four different alternates. 
      Qualitative analysis of the co-cultures once they had been fixed and stained for 
PECAM-1 revealed that the best time to seed the spheroids was +1 day after the 
HUVEC were seeded. Once the spheroids were seeded onto the co-culture, day 4 was 
found to be the optimal day to fix and stain the co-culture. This was the best amount of 
time for vascular growth to be able to determine any directional influence by the 
spheroids. Figure 4.5a+b shows an example of an assay with this time course. The 
density of blood vessels is great enough that it is possible to tell if vascular branching is 
directed towards the spheroid that hasn’t occurred by chance alone. It is not too dense 
that it is likely the spheroids will be seeded directly onto the blood vessels that make it 
difficult to quantify the number of branches. The spheroids have become embedded 
within the co-culture, with blood vessels growing above the plane of the spheroids. As 
shown in Figure 4.5a, SW480 P spheroids typically have less branching of blood 
vessels towards them that are also less dense. In comparison, SW480 V have a greater 
number of and more densely branching vessels towards the spheroids, as shown in 
Figure 4.5b. These are typical images taken of the co-cultures containing the two lines 
of SW480 cell. Due to the amount of time is takes for a co-culture to be established after 
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initial seeding of the NHDFs, I did not have enough time during my MRes to achieve 
n=3 for each different time course. I could not therefore perform any quantitative or 






















































Figure 4.4 – In vitro tumour angiogenesis assay. NHDF and HUVEC were co-cultured 
at concentrations of 3x104 cells/mL and 6x10
4
 cells/mL in 12-well plates respectively until 
confluent and then SW480 P (a) and SW480 V (b) spheroids were seeded. An optimum 
time to seed the spheroids after the HUVEC were seeded was +1 day. Images were 
taken once the cells were fixed and stained with anti-PECAM-1 on day 4. (a) An SW480 
P spheroid in co-culture with PECAM-1 stained vasculature. Fewer blood vessels have 
branches growing towards the spheroid. (b) SW480 V in co-culture, vasculature is 
PECAM-1 stained. More blood vessels have branches growing toward the spheroid and 




The results from this chapter are encouraging, however without quantification or 
statistical analysis of the blood vessel growth towards the spheroids, no conclusion can 
be made as to the effect of VEGF. It is well established that VEGF is a pro-angiogenic 
factor, and its expression is upregulated in a number of cancer cell lines. The effect of 
upregulating VEGF in SW480 cells on blood vasculature was examined. This 
upregulation of VEGF165 in SW480 cells, a stable cell line created by Jimmy Wei, was 
first validated using an immunofluorescence assay. As shown in Figure 4.2, the stable 
cell line overexpressing VEGF produces a greater amount of VEGF than its parent cell 
line. The immunofluorescence captured in Figure 4.3 shows the VEGF being secreted in 
vesicles. The clouds of Alexa Fluor 488 signal that exist apart from the vesicular VEGF 
suggest that the VEGF is being tethered outside of the cell, most probably by the ECM. 
Indeed, VEGF189 and296 isoforms have previously shown to localise to the ECM [77] and 
so VEGF165 would probably follow the same secretion pathway. This immobilisation of 
the VEGF will create a local gradient to the SW480 cells, with a high relative 
concentration close to the SW480 V that decreases in concentration as distance from 
the SW480 V lengthens. VEGF165 has moderate tethering to the ECM and so it will have 
a gradually declining concentration gradient. This VEGF inclination allows ECs to 
migrate towards the VEGF secreting cells, responding to this growth factor binding to 
their VEGF receptors and initiating intracellular signalling events leading to forward 
movement. In tumour physiology, this promotes angiogenesis towards the cancer cells. 
Since this VEGF is trapped in the ECM it was not collected in the cell medium and 
hence would not have been included in the ELISA [VEGF]. Thus, the true concentration 
of VEGF secreted by the SW480 V cell line would be greater than that calculated by the 
ELISA. In vivo, VEGF receptors are saturated at ~10ng/mL. The ELISA conducted using 
the SW480 P and V samples showed that SW480 V secrete ~1/100 of this. However, 
the ELISA used medium taken from SW480 V and SW480 P cells in culture, which 
would combine all the VEGF secreted by the cells in the culture dish and is assumed to 
be evenly spread throughout all the cells. In practice, VEGF secretions form SW480 
cells will be more localised, allowing for a gradient of VEGF to be established.  
       As shown in Figure 4.1, these SW480 cell lines were able to be encapsulated into 
droplets composed of methylcellulose. Using the hanging droplet method of cell 
suspension, the SW480 cells were evenly distributed within the droplets. This clustering 
of SW480 cells localises their secretions. Hence, the local concentration of VEGF 
around the spheroids will be greater than that found by the ELISA. The effect of this 
localised VEGF on blood vessel growth was then examined in EC and NHDF co-culture. 
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       An in vitro tumour angiogenesis assay was set up to investigate the effect of both 
SW480 cell lines on blood vessel growth. A co-culture was established between NHDFs 
and ECs until blood vessels reached maturity. After SW480 spheroids were seeded and 
finished their incubatory period, changes in the vasculature were observed. Results 
from this assay suggest to a potential link between VEGF secretion by SW480 cells and 
the local growth of blood vessels. Figure 4.5 shows the density and general 
directionality of blood vessels surrounding randomly chosen spheroids of SW480 V and 
SW480 P tumour cells. The co-culture containing SW480 P cells has visibly a lower 
density of blood vessels surrounding the spheroid than the co-culture with SW480 V 
cells. These spheroids in figure 4.5 were chosen at random for each co-culture, and so 
the outcome of each can be presumed to follow a general trend for each of the cell 
lines. However, as discussed, there can be no conclusive remark on whether VEGF 
secreted from SW480 spheroids has an effect on blood vessel growth due to the lack of 
experimental replicates for each time course. This is a preliminary experiment requiring 
further co-culture repeats using the time-course suggested by this chapter. Quantitative 
analysis should then be carried out to assess statistical significance between SW480 P 
















Chapter 5 Surface protein labelling of HUVEC 
5.1 Introduction 
All types of cell have an underlying cell polarity. One aspect of their cellular polarity is 
the distribution of surface membrane proteins. Membrane proteins provide the 
characteristic functioning of a particular type and region of membrane. The type of 
protein and its relative amount in a membrane controls the biochemical activity in that 
region. For instance, the inner mitochondrial membrane functions to generate ATP 
using an electrochemical gradient by being endowed with transmembrane ATPase [78]. 
This allows the inner mitochondrial membrane to have a distinct function that is different 
to other organelles. Certain membrane proteins have an asymmetric distribution, being 
present in greater amounts at the apical or basolateral surface of the cell. Conversely, 
they may be non-polarised and be equally distributed at either surface. Transport 
proteins are present within the membrane separating two compartments. The presence 
of these carriers at the membrane allows selective transport across this particular 
membrane [79]. For instance, GLUT-4 is present at the apical surface of adipocytes and 
striated muscle cells. Here, it allows the facilitated diffusion of glucose down its 
concentration gradient from interstitial fluid and into the cytoplasm of adipocytes and 
muscle cells [80]. Due to the fluidity within cell membranes, cells have methods of 
restricting lateral diffusion of membrane proteins to maintain membrane protein 
distribution. Tight junctions are a specialised type of adherence complex that hold cells 
together at their lateral surface to create a tight, continuous layer of cells [2]. As these 
tight junctions are transmembrane, they also serve as a molecular fence to prevent the 
lateral movement of surface proteins within the membrane of the cell.  
        Determining the polarity of membrane proteins within different cell types is an 
ongoing challenge. Epithelial cell surface protein polarity has been studied in detail and 
so there exists an in-depth list of proteins whose surface distribution has been 
determined. Contrastingly, there is much less known about the polarity of ECs. Recent 
research has elucidated, however, the polarity of two membrane proteins present within 
neural microvascular ECs (MVECs) [38]. The polarised receptor distribution of VEGFR1 
and VEGFR2 allows for distinct signalling responses to VEGF-A, an isoform of VEGF 
that is present in both luminal and abluminal tissue. It was proposed that the response 
of VEGFR1, present predominantly at the apical surface of MVECs, to VEGF-A is one of 
cytoprotection. VEGFR2, which is predominantly abluminal, binds to VEGF-A and 
initiates a response to induce increased cell permeability. This research suggests that 
there is further scope for determining EC surface membrane protein polarity.  
85	  
	  
       The aim of the work in this chapter was to further investigate the polarity of 
membrane proteins in HUVECs. I aimed to separately label its surface membrane 
proteins in order to detect for specific proteins on the apical and basolateral surface. To 
validate this method of surface protein labelling, I used immunofluorescence to directly 
stain for proteins at the apical and basolateral surface of HUVEC and compared the 
results of this with that obtained from the surface protein label.  
   
5.2 Results 
5.2.1 Production of a confluent, polarised HUVEC monolayer  
When cells are cultured on surfaces, they adhere to this surface via adhesion 
complexes present at their basal surface. Thus, reagents cannot gain access to this 
surface of the cells. Adding labelling reagents to the culture medium will mainly label the 
apical surface. To resolve this issue, Transwell membrane inserts were used. These are 
permeable devices that support cell culture on their surfaces and allows for passive 
transport of molecules through to reach the basal surfaces of the cells. They allow small 
molecules to enter through the 0.4µm polyester membrane pores, and then reach the 
basal surfaces of the cell culture. The separation of solutions at the apical and 
basolateral surfaces of the cells seeded onto the Transwell, together with its 
permeability, allows these two surfaces to be separately labelled. 
       For the two surfaces of the cells to be separately labelled, there must be stable cell-
cell junctions with no gaps in the monolayer. The confluent monolayer reduces the 
likelihood of the biotinylating reagent being able to diffuse through the cell monolayer 
and incorrectly labelling the opposite surface of the cells. A protocol was developed, by 
researchers in my lab, to support the culture of HUVEC on Transwell inserts to form a 
confluent monolayer. This involved the seeding of HUVEC onto the transwells in EGM-2 
and after a 24 h incubation replacing this media with HIFA medium. I carried out this 
protocol and visualised the cells on the Transwell inserts to assess their confluency. To 
do this, I stained the HUVEC tight junctions and adherens junctions with ZO-1 and VE-
cadherin respectively. I also counterstained the cells with DAPI to visualise their nuclei. 
As shown in Figure 5.1, a confluent monolayer of HUVEC was achieved and hence 





5.2.2 VEGFR1 is apically polarised within HUVEC membranes and becomes 
cleaved when EDTA is added 
Little is known about the polarity of surface proteins in ECs. In addition to this, it is not 
yet fully understood how to biotinylate the apical and basal surfaces of these cells 
separately. Hence, until a protocol is developed and validated that biotinylates both 
surfaces of the cells separately, we cannot gain conclusive evidence regarding the 
polarity of endothelial surface proteins. I decided to validate a method of HUVEC 
biotinylation by staining for surface proteins after the cells had either been apically or 
basolaterally biotinylated, whose polarity within HUVEC membranes has already been 
deduced.  
       Previous research showed VEGFR1 to be apically localised, and VEGFR2 basally, 
within neural MVECs [38] (Figure 5.2). These set off distinct signalling cascades within 
the EC to carry out separate functions. I hypothesised that there, too, would be 
polarisation of other surface proteins in HUVEC cells. To assess the polarity of these 
two surface proteins within HUVEC, Hudson et al used sulfo-NHS-LC biotin to label 
surface proteins on cells cultured on Transwells. It had been well established that basal 
biotinylation is relatively much weaker than apical biotinylation. So, Hudson and 
colleagues incubated EDTA as well as the biotinylation reagent at the apical surface to 
biotinylate both surfaces of the HUVEC. EDTA is a chelating reagent which binds 
divalent metal ions and inactivates cell-cell junctional complexes, creating gaps in 
between cells. It therefore allows access to the basal surface of the cells. So, the 
biotinylation reagent can label both the apical and basal cell surface. Relative 
distributions of surface proteins can be deduced at the apical and basolateral surfaces 
of cells from western blotting. Exposure of the apical surface of cells to either labelling 
reagent or labelling reagent with EDTA allows labelling of the apical or both apical and 
basolateral surfaces respectively. Looking at the relative thickness of bands on a 
western blot for both these two conditions reveals relative distributions of surface 
proteins.  
        Staining with VEGFR1 antibody confirmed that VEGFR1 is apically localised 
(Figure 5.4). There was a band present at ~120KDa with no EDTA added, possibly 
representing isoform 1 (150KDa) which ran incorrectly on the gel. EDTA treated HUVEC 
did not show this band. Instead, these treated cells generated two smaller bands at ~60 
and ~68 KDa which suggests a cleavage event has taken place on the receptor, due to 








   
  
Figure 5.1 – HUVEC cultured on Transwell insert forms confluent 
monolayer. HUVECs were seeded at concentration of 2x10
5
 cells/mL on a 
Transwell membrane insert. After a 72hr incubation, cells were fixed and stained 
with ZO-1 (red), VE-cadherin (green) and DAPI (blue). Cells were imaged by 
confocal microscopy at low magnification to get an impression of their confluency. 





























Figure 5.2 – Hypothesised distribution of VEGFR1 and -R2 in neural 
microvascular endothelial cells (MVECs). Hudson et al conducted several in vivo 
and in vitro experiments on neural MVECs and found that vascular permeability 
was only increased when VEGF-A was added to the basal surface of the cells. 
There was a reduction in the amount of junctional claudin 5 (Cldn5), an integral 
component of cell-cell tight junction complexes, when added basally, indicating the 
loss of such cellular junctions and hence an increase in paracellular permeability. A 
cytoprotective response was only seen when apical VEGF-A bound to VEGFR1, 
eluding to its presence predominantly at the apical membrane. Diagram taken from 



























Figure 5.3 – Western blot of VEGFR-1 and -2 with and without EDTA added 
apically. 5mg/mL sulfo-NHS-LC-biotin was incubated with HUVEC, seeded at 2x10⁵ 
cells/mL on Transwells, for 30 mins at 37°C. HUVEC incubated with 1mM EDTA 
shown by lanes labelled apical + EDTA. Lysis medium ran on western blot and 
stained for VEGFR-1 and -2. VEGFR-1 is present at the apical surface of HUVEC 
shown by band at ~120kDa.  The addition of EDTA generates two smaller bands, 
which could resemble two regions of a cleaved VEGFR1 monomer. The event which 
causes two smaller bands to be produced when EDTA is added occurs either 
intercellularly or extracellularly. It cannot be determined if VEGFR-1 is present at the 
basolateral surface of the HUVECs. No VEGFR-2 signal detected, possibly due to 


















5.2.3 Biotinylation reagent can label the apical and basolateral surfaces of 
HUVEC without the need for EDTA 
As shown, EDTA cleaved VEGFR-1 and hence we cannot deduce from this method its 
basolateral polarity. This outcome is worrying, as using EDTA may give a false positive 
result for a protein when this sample is applied to mass spectrometry. I set about to 
assess the plausibility of being able to efficiently biotinylate the apical and basolateral 
surfaces without the use of EDTA. 5mg/mL sulfo-NHS-LC-biotin was added to both the 
top and bottom compartments of the Transwell, and its ability to label to the apical and 
basolateral surfaces of the HUVEC was studied via fluorescence microscopy.  
       Immunostaining showed that the biotinylating reagent can label the apical and 
basolateral cellular surfaces (Figure 5.4). Sulfo-NHS-LC-biotin, added apically, labels 
the apical and basolateral surfaces of the HUVEC. The streptavidin Alexa Fluor™ 594 
signal can be seen at the top and bottom of the cell in relatively equal amounts. In 
contrast, when added to the bottom Transwell compartment, it preferentially labels the 
basolateral surface of the HUVEC. The biotin label is relatively evenly distributed, 
reflecting the fact that it modifies primary amine groups on cell surface proteins. These 
include lysine, a relatively abundant amino acid, and amino-termini of polypeptides, 
which occur on every protein. There is a strong fluorescent signal at the basolateral 
surface of the cells when basally biotinylated; the ECM is protein dense hence it binds 
to biotin and may give the appearance that the biotin is binding to the basal surface of 
the HUVEC. In either case, the biotinylating reagent has been able to reach the primary 
amine groups by diffusing through the Transwell membrane. 
       The mean pixel intensities taken at the top and bottom of the cells in the images 
gives an indication of how strong the streptavidin Alexa Fluor™ 594 signal is and hence 
a comparison of the amount of biotinylating reagent present at each of these surfaces. 
ECs are very thin, to carry out their specialised functions, and hence fluorescence 
signals at the apical and basal surfaces of these cells are difficult to resolve. Here, I 
analysed the relative pixel intensities at the top and bottom of the nucleus as this is the 
widest section through the cell. When Sulfo-NHS-LC-biotin was added to the top and 
bottom compartments of the Transwell, greater mean Alexa Fluor™ 594 signals were 
obtained from the apical and basal surfaces of the cells respectively (Figure 5.5). This 
shows that the biotinylating reagent preferentially labels HUVEC surface proteins which 
face the compartment that the label was added to. Indeed, when added to the basal 
surface of the cells (bottom Transwell compartment) the mean pixel intensity, averaged 
across five points on the confocal image, for the basal surface of the cell membrane 
91	  
	  
was 74.03. Comparing this to the mean signal intensity at the apical surface, calculated 
as 35.48, shows that this is more than twice as large. When added apically (top 
Transwell compartment) the biotinylating reagent labels more proteins at the apical side 
of the HUVEC, as the mean pixel intensity here was 64.8, compared to 59.47 at the 
basal side. However, these averages are very similar and so we cannot deduce that, 
when added apically, the sulfo-NHS-LC-biotin preferentially labels the apical surface 
over the basal surface. The similarity with which the biotin label modifies the apical and 
basal surfaces when added to the top Transwell compartment is a cause for concern; 
when apically biotinylated surface proteins are taken away for proteomic analysis, this 
will be a mix of relatively similar amounts of apical and basal surface proteins. Thus, the 
polarity of such proteins will be incorrectly determined.  
 
5.2.4 Biotinylation at the apical surface is more efficient than at the basal 
surface 
Biotinylation is possible at both the apical and basal surfaces of HUVEC on Transwells 
(Figure 5.4). However, previous studies have shown that this process is relatively less 
efficient at the basal surface of the cells on Transwells than the apical surface [81]. I 
wanted to conduct an experiment to determine the ability of a reagent to label the apical 
surface relative to basal surface of HUVECs grown on Transwell inserts. To do this, I 
added sulfo-NHS-LC-biotin at the same concentration to the apical and basal surface of 
the HUVECs on Transwells. Due to evidence of poor basal surface labelling, I labelled 
the basal surfaces of samples with increasing concentrations of sulfo-NHS-LC-biotin. 
Samples were taken after the cells were lysed and analysed by western blotting. This 
protocol assumes that there are similar amounts of total protein at the apical and basal 
surfaces of cells. 
       As shown, when 5mg/mL sulfo-NHS-LC-biotin is added apically this results in a 
greater relative amount of total protein being labelled then when the same concentration 
is added basally (Figure 5.6). This is consistent with findings from previous papers [81]. 
The efficiency of biotinylation at the basal surface increases when increasing amounts 
of biotinylating reagent are added to the HIFA medium. This efficiency never reached 
that of the sample that was apically labelled despite being in 2x and 4x greater 
concentrations respectively. Thus, I found it is much more difficult to label proteins 
present on the basal surface of cells on a porous membrane even when the amount of 
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Figure 5.4 – Apical and basolateral HUVEC surface membrane proteins are 
able to be labelled when reagent added apically or basolaterally, 
respectively. HUVEC cultured at 2x10⁵ cells/mL on Transwell inserts and 
incubated for 30 mins at 37°C with a green CellTracker™ and a) 0.2mg/ml sulfo-
NHS-LC-biotin added to the apical surface of HUVEC and b) 0.4mg/ml sulfo-
NHS-LC-biotin added to the basal surface of HUVEC. Cells were then fixed and 
stained with DAPI (blue) and streptavidin Alexa Fluor™ 594 (red). XYZ 
projections through apically and basally biotinylated HUVEC are shown. Scale 


































Figure 5.5 – Graph showing the mean pixel intensities of labelled HUVEC apical 
and basal surfaces.	  Mean pixel intensities were averaged at each surface across 5 
cell nuclei on each fluorescence confocal image. Sulfo-NHS-LC-biotin was added to 
the apical and basal surfaces of HUVEC, and the mean pixel intensities of 
streptavidin Alexa Fluor™ 594 calculated at each surface. This equates to the amount 
of biotin label present at each surface when label added apically and basally to the 
cells.	   Statistical analysis was performed using a 1-way ANOVA on all the data 
followed by a Tukey multiple comparison test on data obtained from day 4, *p ≤ 0.05. 






























Figure 5.6 – Biotinylation of the apical surface is greater than the basal 
surface of HUVEC. HUVEC seeded at 2x10
5
 cells/mL on 0.4µm Transwells and 
biotinylated from either apical (Apical) or basolateral (BL) surface of Transwell. 
5mg/mL sulfo-NHS-LC-biotin added to the top Transwell compartment and proteins 
at the apical surface of the HUVEC were very efficiently labelled. Basal surfaces 
biotinylated via addition of 1x, 2x and 4x the amount of sulfo-NHS-LC-biotin that is 
added apically, added to the bottom compartment of the Transwell. Increasing the 
concentration of sulfo-NHS-LC-biotin increases basal biotinylation. After 
solubilization, the labelled proteins were separated by SDS PAGE and subjected to 
























5.2.5 Optimising labelling at the apical surface of HUVEC 
As shown in figure 5.7, the ability of sulfo-NHS-LC-biotin to label the apical surface 
proteins of HUVEC is greater than basal surface proteins. Even though greater total 
proteins can be labelled at the apical surface, in labelling the apical surface proteins 
some basal surface proteins are also labelled (Figure 5.5). For separate proteomic 
analysis of proteins at the apical and basal surfaces of the cell, these two surfaces must 
be labelled independently. To increase the relative labelling of apical compared to basal 
surface proteins, the amount of time the biotinylation reagent is incubated with the 
apical surface of the HUVEC on Transwells was reduced. The effect of this is twofold; 
there is less time for the labelling reagent to pass through any leaks in the monolayer, 
and less time for apical surface proteins to be endocytosed and recycled to the basal 
surface of the cell before fixation and hence lost from the apical surface of the cell. 
Previous western blots were the result of a 30 min incubation at 37°C. Here, the 
biotinylation is carried out over a time course of 30 min (Figure 5.8). 
       Western blot analysis revealed that total biotinylation increases over time (Figure 
5.7a). The amount of biotinylated protein, however, saturates by 20 min. A 5 min 
incubation resulted in minimal protein being labelled. It is important here to assess 
relative biotinylation reagent labelling at the apical and basal surface of the HUVECs at 
each time point. Immunofluorescence using Alexa Fluor™ 594 streptavidin was carried 
out to visualise the localisation of biotin on the HUVEC surface membrane (Figure 5.8b). 
Image analysis of the confocal IF images showed a greater relative amount of 
streptavidin 594 signal at the apical surface than the basal surface during 5, 10 and 20 
min incubations. It appears that relative apical to basal surface labelling increases when 
the incubatory period is reduced. Quantification of these images was required for 
justification of these analysis. Average pixel intensities were taken of streptavidin 594 
signal at the apical and basal surface of the HUVEC, taken either side of the nuclei of 
five different cells for each time-point. A mean average pixel intensity for each of the 
apical and basal surfaces allowed a ratio of apical to basal labelling to be calculated for 
each time-point (Figure 5.7b). 5 and 10 min incubations with the biotinylation reagent 
gave greater apical than basal labelling. Incubations longer than this reduced the apical 
binding efficiency relative to basal surface binding, with a 30 min incubation having 
greater basal than apical binding. A 10 min incubation gave the greatest ratio of 
apical/basal labelling, at 1.62.  Therefore, reducing the incubatory period generally 
increases apical to basal labelling. However, 1.62x greater labelling at the apical surface 
than the basal surface, when the labelling reagent is added apically, indicates that this 
surface has not been labelled in isolation.  
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Figure 5.7a – The amount of surface biotinylation increases with increasing 
incubation time. HUVEC seeded at 2x10⁵ cells/mL on Transwells were incubated 
with 5mg/mL sulfo-NHS-LC-biotin, added apically, at 37°C. Increments in 
incubation time shown, with intervals of 5, 10, 20 and 30 mins. Minimal protein is 
labelled when biotin reagent incubated on Transwell for 5 mins. The amount of total 
protein labelled increases substantially at incubation time of 10 min. 20 min is the 
saturation point for biotinylation of proteins by sulfo-NHS-LC-biotin, as it is the time-
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Figure 5.7b – The relative apical to basal surface labelling declines with 
increasing incubation time. HUVEC seeded at 2x10⁵ cells/mL on Transwells 
incubated with 5mg/mL sulfo-NHS-LC-biotin, added apically, at 37°C. Increments 
in incubation time shown, with intervals of 5, 10, 20 and 30 mins. After a 5 min 
incubation, 1.58x more apical proteins are biotinylated than proteins at the basal 
surface. At 10 min this rises slightly, however after this time the ratio of 
apical/basolateral surface protein labelling declines. The most promising relative 
binding is at 10 min, at 1.62x A/Bl. Scale bar = 10µm.  
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5.2.6 Incubating HUVEC with biotinylating reagent at 0°C does not increase 
relative apical binding  
As shown in Figure 5.7, reducing the amount of time that the biotinylating reagent was 
incubated with the apical surface of HUVEC was effective at increasing the relative 
amount of label at the apical surface than the basolateral. However, there is still some 
degree of basolateral surface labelling and so this method is only partly effective at 
increasing apical labelling independently from basolateral labelling. The same 
experimental procedure was repeated at 0°C in an attempt to label the apical surface in 
isolation. At 0°C, cellular processes slow down as the metabolism of the cell declines. 
As a result, cellular trafficking slows, and so less biotinylated apical surface proteins will 
be endocytosed and taken to the basolateral surface when compared to the same 
experiment carried out at 37°C. 
      Immunofluorescence confocal microscopy suggests that HUVEC incubated with 
biotinylation reagent at 0°C for 5 and 10 min gave equal or greater biotin binding at the 
apical surface compared with the basal (Figure 5.8a). This is demonstrated by similar or 
more streptavidin 594 staining at the apical relative to the basolateral HUVEC surface. 
After 10 min, more proteins at the basal surface than the apical surface were 
biotinylated. Quantification of surface labelling using image analysis software showed 
that there was similar or more apical surface binding relative to basal at 5 and 10 min 
incubations (Figure 5.8b). However, these ratios are lower than the corresponding time 
points at 37°C. 20 and 30 min incubations gave greater amounts of biotin labelling at the 
basal surface than the apical. Again, these ratios are lower than the corresponding 
values for HUVEC at 37°C, hence cold experimental conditions do not increase the 
relative amount of label present at the apical surface of HUVEC compared to 
basolateral surfaces. Lower apical/basolateral label ratios for corresponding HUVEC 
incubations at 0° compared to HUVEC at 37° suggests an increase in label, and hence 
apical surface protein, being transferred to basolateral surfaces. Under cold cellular 
conditions, cell-cell junctions can become ‘leaky’ as tight junctions detach and cells 
‘round up’. This allows the biotin reagent to pass through intercellular gaps and become 
exposed to the basolateral surface. However, lower magnification images taken of the 
HUVEC cultured on Transwells (Figure 5.1) shows that they form confluent monolayers 
of cells with no visible gaps. This creates uncertainty as to how the label is reaching the 
basolateral layer. From these previous experiments, it is clear that labelling the apical 
surface in isolation from the basolateral surface is very difficult. Label repeatedly 
reaches the basolateral surface, even when intracellular trafficking is slowed.  
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Figure 5.8 – Incubating HUVEC with biotinylation reagent at 0°C gives lower 
relative apical to basal surface protein labelling when compared to warm 
conditions (37°C).  HUVECs seeded at seeded at 2x10⁵ cells/mL on Transwells on 
ice were incubated with 5mg/mL cold sulfo-NHS-LC-biotin, added apically. Increments 
in incubation time shown, with intervals of 5, 10, 20 and 30 mins. Immunofluorescence 
at each time-point shown, with quantitative data representative of the ratio of 
apical/basal streptavidin 594 signal. 5 min cold incubation with the labelling reagent 
gave almost equal labelling at the apical and basolateral surfaces of the cells. The 
binding efficiency of the biotinylation reagent was greatest at 10 min cold incubation, 
however time points after this gave greater basal binding efficiency. Relative apical to 
basolateral surface labelling at each time-point lower than corresponding time-points 
at 37°C. Scale bar = 10µm. Statistical analysis was performed using a 1-way ANOVA 
on all the data followed by a Tukey multiple comparison test on data obtained from 
day 4, *p ≤ 0.05. The graph shows the mean ± SEM of five experimental replicates. 
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5.2.7 Immunofluorescence is an effective method of directly imaging and 
quantifying surface protein polarities 
In order to observe how reliable the method of apical or apical and basolateral surface 
biotinylation is, a method to directly image proteins at the apical and basolateral surface 
was developed in parallel. Direct methods to visualise surface proteins do not require 
the addition of labelling reagent. Using a direct method, the fluorophore will simply bind 
to a surface protein via a primary and secondary antibody. It is a more reliable method 
of identifying surface proteins and can be used as a cross-reference when deciding the 
validity of using biotin to label surface proteins in isolation.  
      This alternate method involves labelling HUVEC with immunofluorescent antibodies 
that are specific for surface proteins to be identified. These proteins can then be 
detected via confocal microscopy and their polarisation deduced via analysis of the 
fluorescence signal present at each surface domain. XY as well as XYZ images were 
captured, with z-stacks taken with intervals of 0.13µm to obtain a z-projection of around 
80 stacks. The polarity of proteins on the HUVEC surface membranes were deduced by 
image analysis software of the confocal images. The mean pixel intensity of the 
secondary antibody 594nm signal was compared at the apical and basal surfaces of the 
cells to deduce the relative antibody binding at these two surfaces. The challenge here 
is that HUVEC cells are extremely thin, and so it is difficult to differentiate signals at the 
apical surface of the cells from signals at the basal surface. To get around this issue, 
these average pixel intensities were taken from regions at the apical and basal regions 
of the nuclei at the HUVEC surface membrane, as this is the widest point within a cell.  
       This method, however, is relatively low throughput and is costly, and also relies on 
the antibodies being effective. Ideally, this experimental procedure would only be 
established to validate HUVEC surface protein biotinylation. However, as previously 
demonstrated it is not possible to label apical or basolateral surface proteins in isolation. 
Determining the surface proteome of HUVECs therefore relies on this direct 
immunofluorescent method of protein identification.  
       Immunofluorescence microscopy of HUVEC surface proteins is likely to give 
reliable results as surface proteins remain immobile at the time of protein staining. To 
validate this method of protein labelling, strong markers of the apical and basolateral 
surfaces need to be stained and identified. Due to their cellular function, these proteins 
will be localised to either the apical or basolateral surface of HUVEC specifically. 
Staining for these will provide critical indication as to whether the use of fluorophore 
conjugated antibodies will give valid proteomics data for other surface proteins. 
       Integrin α5 and ICAM-1 primary antibodies were used in the initial immunostaining 
101	  
	  
procedure as these are highly established HUVEC surface proteins. Based on their 
function, integrin α5 is likely to have a polar distribution at the basolateral surface 
membrane. This protein is one monomer of a heterodimer constituting a cell adhesion 
glycoprotein (integrin) that binds to fibronectin within the ECM. This binding aids in cell 
adhesion to the ECM and in intracellular signalling transduction from the ECM to 
promote survival, proliferation, growth and differentiation. ECM is situated at the 
basolateral surface of ECs and hence this is where the integrin α5 will be primarily 
localised. ICAM-1 is a cell adhesion molecule. ICAM-1 binds to LFA-1, an integrin 
present on immune cell surface membranes, and provides initial binding that brings the 
immune cell in close proximity to the endothelium. Once at the endothelium, firmer 
binding, which is more characteristic of an immune reaction, takes place between 
integrins present on the immune cell and the endothelium. This promotes diapedesis of 
the immune cell across the endothelium and into the underlying tissue where it acts to 
clear infection and repair damage. I hypothesised that ICAM-1 would be expressed 
principally at the apical surface of HUVEC, so that it can be exposed to immune cells 
within the blood. ICAM-1 is constitutively expressed, albeit at a low level, in ECs and 
immune cells. When inflammation if triggered, expression of ICAM-1 is dramatically 
increased on both sets of cells. This promotes an immune response large enough to 
control any infection or damage within an area of tissue. I was therefore interested in 
confirming the polar distribution of these two proteins within HUVECs, giving validation 
to this technique of protein labelling.  
       For this initial screen using integrin α5 and ICAM-1 primary antibodies, permeable 
Transwells were used as a surface to culture HUVECs. These provide a better surface 
to obtain a confluent monolayer of cells, essential for maintenance of surface protein 
polarity. They also better mimic the physiological environment and so the architecture of 
the cells will be as close to that as in normal physiology as possible. Figure 5.9a shows 
that, indeed, integrin α5 is present predominantly at the basolateral surface of HUVEC 
and ICAM-1 is situated mostly at the apical surface. Moreover, integrin α5 appears to 
form fibrillar structures. This is characteristic of α5β1 integrins, heterodimers of α5 and 
β1 subunits. Fibronectin binding to the α5 subunit of the integrin promotes α5β1 
oligomerisation and fibril formation. Figure 8a shows only one HUVEC expressing 
ICAM-1. Under normal conditions, this protein is not expressed in high enough amounts 
to be detected by immunofluorescence. There will have had to be some form of 
stimulation for this cell to upregulate its ICAM-1 expression and trafficking to the apical 
surface for this signal to be detected. Quantification of the immunofluorescence data for 
integrin α5 and ICAM-1 confirms their opposing polar distribution. The ratio of mean 
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pixel intensity for integrin α5 at the apical and basolateral HUVEC surfaces is 0.73, 
which falls below 1, hence there is a greater amount of integrin α5 present at the 
basolateral surface of the cell than the apical. Contrastingly, ICAM-1 has an apical to 
basolateral ratio of greater than 1, at 1.68. ICAM-1 is present more at the apical surface 
than the basolateral surface. The ICAM-1 signal ratio SEM is relatively greater than the 
SEM for integrin α5, its average ratio fluctuating across the 3 sets of repeats to a greater 
extent.  
 
5.2.8 HUVEC cultured on coverslips reproduce membrane surface protein 
polarity as that seen on Transwells 
As shown previously in Figure 5.9, integrin α5 and ICAM-1 display polar distribution on 
HUVEC surface membranes when HUVECs are cultured on Tranwells. To scale up this 
screen, HUVECs cultured on coverslips were investigated. Coverslips allow greater 
reproducibility of results, and it is easier to culture cells on this surface relative to 
Transwells. I was interested in reproducing the results from the initial Transwell 
experiment outlined above, so again I did a screen for integrin α5 and ICAM-1. This was 
to validate that the use of coverslips for HUVEC culture generates the same surface 
protein polarity as with Transwells. 
       HUVEC were seeded on coverslips and grown until confluency and then prepared 
for immunofluorescence as appropriate. Again, confocal images were taken of XY and 
XYZ sections of the stained HUVEC, and average pixel intensities at the apical and 
basolateral surfaces deduced. Figure 5.10 shows that each protein displays a similar 
staining pattern to that generated on the HUVEC grown on Transwells. integrin α5 
shows more staining at the basolateral surface, which arranges into extracellular fibrils 
concurrent with that seen on Transwells. ICAM-1 shows apical surface localisation as 
seen on Transwells. In addition, the ratio of apical: basolateral signal follows the same 
pattern as previous; integrin α5 generates a ratio of 0.60 and ICAM-1 a ratio of 2.81. 
Again, ICAM-1 displays a substantially greater amount of fluctuation regarding mean 
relative intensities. These are promising results as they reproduce the results and 
patterns of antibody staining as seen using HUVEC on Transwells. From this, it can be 





























ICAM-1  Integrin α5  
Figure 5.9 – Integrin α5 is basolaterally polarised and ICAM-1 is apically 
polarised in HUVEC grown on Transwells. HUVECs were cultured on Transwells 
at 2x10⁵ cells/mL and then fixed and stained with DAPI (blue) and for integrin α5 
(green) and ICAM-1 (red). a) XY and XYZ images were captured using confocal 
microscopy. The polarity of both these proteins can clearly be seen from above and 
below the nucleus (DAPI stained to see thickest part of cell). b) The ratios of apical: 
basaolateral pixel intensities were deduced from the XYZ images using imaging 
software. The bar graph shows the mean ± SEM of three experimental repeats for 



















































Integrin α5 ICAM-1  
Figure 5.10 – Integrin α5 is basolaterally polarised and ICAM-1 is apically 
polarised in HUVEC grown on coverslips. HUVECs were cultured on glass 
coverslips at 6x10⁴ cells/mL and then fixed and stained with DAPI (blue) and for 
ICAM-1 and integrin α5 (red). a) XY and XYZ images were captured using 
confocal microscopy. The polarity of both these proteins can clearly be seen from 
above and below the nucleus (DAPI stained to see thickest part of cell). b) The 
ratios of apical: basaolateral pixel intensities were deduced from the XYZ images 
using imaging software. The bar graph shows the mean ± SEM of three 




























5.2.9 Some HUVEC surface proteins show a propensity for either the apical 
or basolateral surface of HUVEC grown on coverslips 
As shown from Figures 5.9 and 5.10, integrin α5 and ICAM-1 show polarity within 
surface membranes of HUVEC grown on coverslips and Transwells. The reproducible 
data generated from both experiments allows for the use of coverslips as a surface for 
HUVEC culture and staining. To further the proteomics data generated from previous 
HUVEC staining, I was interested in determining the polarity of a number of other 
membrane proteins known to be on HUVEC surface membranes. I began by staining for 
VEGFR-1 and VEGFR-2, as it has been suggested in a paper published by N. Hudson 
and colleagues [38] that VEGFR-1 shows apical polarity and VEGFR2 basolateral in 
neural MVECs. This paper proposes this apicobasal distribution due differential 
apicobasal VEGF signalling seen at vascular blood-neuronal barriers. I was interested if 
this distribution applies to HUVEC as well as MVECs. 
       Using the immunofluorescence protocol described above, HUVECs were stained 
with VEGFR-1 and VEGFR-2 primary antibodies. After incubation with a fluorophore-
conjugated secondary antibody and DAPI, the HUVECs were imaged under a confocal 
microscope. Both VEGFR-1 and VEGFR-2 gave strong signals that could be detected 
and imaged. Figure 5.11 shows the distribution of VEGFR-1 and VEGFR-2 in HUVEC 
grown on coverslips. An issue with clarity arose with the staining for VEGFR-1, however 
it is evident from these XYZ images that VEGFR-1 is relatively non-polarised. Its apical: 
basolateral ratio is 0.84, a value close to 1, indicative that it is present both and the 
apical and basolateral surface of the HUVEC in almost equal amounts. VEGFR-1 looks 
to be concentrated in the Golgi apparatus, positioned around the circumference of the 
nucleus. It is therefore not positioned directly above and below the nucleus at the 
surface membrane. Occupying a more lateral position from the nucleus within the 
cytoplasm, the signal is not included in the measurements taken from the apical and 
basolateral surfaces. It may therefore have the appearance from the XYZ images of 
being non-polar in surface membranes, but this might be caused by signal originating 
from the Golgi. Contrasting to VEGFR1, VEGFR2 has a polar distribution. From the XYZ 
images in Figure 5.11, it is clear that VEGFR2 is present in greater amounts at the 
basolateral surface of HUVEC. Indeed, the ratio of apical/basolateral signalling is 0.56 
meaning that there is nearly twice as much VEGFR2 present at the basolateral surface 
than the apical. This value, however, is not low enough to say with any real 
conclusiveness that VEGFR2 is basolaterally polarised.  
       The result from VEGFR2 was a promising start, as it demonstrated that HUVEC 
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surface proteins may show polarity. Taken further, other HUVEC surface proteins were 
stained for using the same immunofluorescence protocol. A further six surface proteins 
were tested for in the immunofluorescence assay: clathrin heavy chain (CHC), PECAM-
1, P-glycoprotien, podocalyxin, robo 4 and flotillin 2. Due to efficacy variability of the 
primary antibodies, some of the immunofluorescence images failed to show a signal, or 
this signal was too weak to quantify. As a result, the polarity of these proteins could not 
be deduced. Figure 5.12 is a table showing the function of all the proteins investigated, 
as well as the outcome of the immunofluorescence experiment.   
       Of those tested, CHC and PECAM-1 antibodies generated a signal that could be 
detected and imaged (Figure 5.11). The remaining four antibodies failed to be effective 
at staining the HUVEC surface proteins. PECAM-1 is a major constituent of endothelial 
intercellular junctions and is involved in the extravasation of immune cells during 
inflammation. Its function implies that PECAM-1 will be laterally distributed and hence 
more or less non-polarised across the apical-basolateral axis. Figure 5.11, however, 
shows PECAM-1 to have a more apical polarity as the confocal image has a greater 
amount of staining visible above the nucleus than below. The apical/basolateral ratio, 
too, suggests an apical polarity. This ratio, 1.43, alludes to there being almost 50% 
more PECAM-1 present at the apical HUVEC surface membrane than at the 
basolateral. Again, this value is not great enough to conclusively say that PECAM-1 is 
apically localised, as there is still a substantial amount present at the basolateral 
surface.  
       CHC is the protein component composing the coat of vesicles and pits involved in 
vesicle trafficking. The amount of material endocytosed equals that which is exocytosed 
for a cell to achieve a steady trafficking state and homeostasis. Additionally, there are 
similar amounts of proteins at the apical and basolateral surfaces of cells. This would 
imply that there will be similar amounts of CHC coated pits at the apical surface of the 
cell as the basolateral surface. However, a greater amount of trafficking is likely to occur 
at the apical surface in HUVEC as this is in contact with the blood stream and hence 
with a more active trafficking environment. This is reflected in the apical: basolateral 
ratio, 1.31 (Figure 5.11). There is a greater average amount of CHC at the apical 
surface membrane than the basal, but again this value is too close to 1 for any real 


































Figure 5.11 – HUVEC surface proteins show a propensity for either the apical or 
basolateral surface of HUVEC grown on coverslips. Coverslips were cultured with 
6x10⁴ cells/ml and then fixed and stained with DAPI (blue) and for VEGFR-1, VEGFR-
2, PECAM-1 and CHC (red). a) XY and XYZ images were captured using confocal 
microscopy. The polarity of both these proteins can clearly be seen from above and 
below the nucleus (DAPI stained to see thickest part of cell). b) The ratios of apical: 
basaolateral average pixel intensities were deduced from the XYZ images using 
imaging software. The bar graph shows the mean ± SEM of three experimental 
replicates for VEGFR-1, VEGFR-2, PECAM1 and CHC; n=3. Scale bar = 10µm. 
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The results from this chapter have showed that it is not yet possible to separately label 
HUVEC surface proteins without some label being lost to the other surface. Biointylation 
reagent added to the apical surface of the HUVEC resulted in label being observed at 
the basolateral surface, and vice versa. Furthermore, the ability of the reagent to bind to 
the basal surface was not as good as the apical surface. Both of these results combined 
invalidates any results obtained using proteins that have been labelled in this way.  
       The results from figures 5.5 and 5.6 show that sulfo-NHS-LC-biotin labels a greater 
amount of total protein when added apically, however this is distributed relatively evenly 
at the apical and basolateral surfaces. Less total protein is labelled when label added to 
the basolateral surface of the HUVEC, even when 4x as much biotin reagent added, 
reflecting the fact that it is less able to label proteins when added to this surface. 
Labelling from this surface, however, labels twice as much protein at the basolateral 
surface relative to apical. It can be deduced, then, that labelling from the apical surface 
is much more efficient at labelling surface proteins, however a relatively large amount of 
these labelled proteins are at the basal surface when the cells are fixed. When added 
basally, the biotinylation reagent struggles to reach the basal surface proteins to label 
them compared to when the reagent is added apically. These proteins are mostly 
situated at the basolateral surface when the cells are fixed and are likely to largely be 
constituents of the ECM. Taken further, for proteomic analysis of the two separate 
HUVEC surfaces, these two surfaces must be labelled independently. 
       In another attempt to label the apical surface of HUVEC in isolation, the incubatory 
times of HUVEC with the biotintinylation reagent at 37° and 0°C were reduced (Figure 
5.7 and 5.8). An increase in apical surface protein labelling relative to basolateral 
surface protein labelling was seen for 5 and 10 min incubations at both temperatures. 
However, this difference in labelling across the two surfaces was relatively non-distinct.  
Reducing the temperature to 0°C did not improve relative apical to basolateral labelling.  
       As shown, this method of surface protein labelling cannot be used when 
researching proteomics as it is not possible to label one cell surface in isolation from the 
other. Biotinylated proteins are isolated from lysed cells using streptavidin, which cannot 
differentiate the apical from the basolateral cell surface. Hence, surface proteins from 
both the apical and basolateral surfaces will be analysed using SDS PAGE and western 
blotting. The polarity of surface proteins cannot be determined as there is no separation 
of proteins from each surface.  
       The results from analysis of HUVEC surface protein polarity using 
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immunofluorescence show great promise. This protocol uses fixed HUVECs, which 
have been surface membrane permeabilised, and so the polarity of proteins at the point 
of fixation can be accurately determined. Highly specific, tight binding of antibody-
antigen ensures little cross-specificity and is highly accurate. Validation of this method 
using strong apical and basolateral markers, ICAM-1 and integrin α5 respectively, on 
Transwells was successful (Figure 5.19). However, these apical: basolateral ratios are 
still close to 1, meaning they are only marginally polarised at the apical and basolateral 
surfaces respectively. Their polarity pattern was reproduced on coverslips, which meant 
that it was possible to scale up the experiment to screen for other proteins.  
       Results obtained regarding the polarity of VEGFR-1 in HUVEC (Figure 5.11) 
contradicted that of Hudson et al [38]. This paper suggested that VEGFR1 was apically 
polarised in mouse MVECs isolated from cortical grey matter. This was the result from 
in vitro cryoimmunogold electron microscopy and both in vitro and in vivo 
immunofluorescence. However, my in vitro immunofluorescence assay of VEGFR-1 in 
HUVEC showed it to be basolaterally polarised. This discrepancy may be due to the 
different micro-environment of the ECs (brain vs umbilical cord matter), or the different 
animal model used.  
       Further immunofluorescence experiments were carried out on different surface 
proteins to determine their polarity within HUVECs (Figure 5.12). Neither PECAM-1 nor 
CHC produced a polarity index indicating any absolute polarity. VEGFR-2, which had 
previously suggested was basolaterally polarised [38], too, produced a relatively weak 
polarity index when assayed for immunofluorescence.  
       In summary, it was not possible to establish a protocol for labelling HUVEC apical 
and basolateral surface proteins separately. Initial protocols used EDTA as a reagent to 
increase the passage of labelling reagent to the basolateral surface when added 
apically. However, this is likely to interfere with the surface proteins; this research 
suggested that EDTA cleaved VEGFR-1. It is possible to label surface proteins without 
EDTA, the labelling reagent being incubated with the HUVEC at the apical or 
basolateral surfaces. At both surfaces however, the labelling reagent failed to remain at 
its intended surface. It was possible to demonstrate a more valid method of surface 
protein labelling using immunofluorescence. Some of these followed a polar distribution 
that was expected from their physiological function. Integrin α5 and ICAM-1 patterning 
agreed with initial predictions, however stronger relative staining patterns are needed to 
provide any conclusive evidence of surface protein polarity. This method is suitable for 





The study of the endothelium in recent research has shown that it is at a hub of 
homeostasis, controlling normal physiological processes and being implicated in many 
pathologies. Work in this research project was aimed at studying ECs in cell culture to 
understand the fundamental cell biology of the endothelium. In doing this, I set out to 
learn the basics of EC culture and apply this to more complex cellular assays to study 
the interaction of ECs with other cell types in vitro and determine the polarity of a 
number of important EC surface proteins.  
       First, I learnt how to culture ECs in vitro and that their requirements are more 
complex than first thought. This cell type has a specialist requirement for culture media 
composition. The growth and proliferation of HUVEC was optimal when Lonza EGM-2 
media was used, compared to different culture media compositions and other suppliers. 
EGM-2 media containing refined growth factors and signalling molecules at specific 
concentrations to promote optimal HUVEC proliferation. Having a statistically greater 
effect on HUVEC proliferation, I then used Lonza EGM-2 media as the culture media for 
future culture assays.   
       Secondly, having optimised HUVEC culture conditions I aimed to determine 
whether different biomaterials were suitable to support HUVECs grown on their surface. 
From this it was evident that not only do HUVECs not form a complete monolayer with 
stable cell-cell junctions when cultured on TiO2, they are also prone to developing 
markers of genetic instability. Fluorescence microscopy of DAPI and phalloidin stained 
HUVEC showed the low confluency and high micro-nuclei and chromatin bridges in 
these cells grown on TiO2.  
       The elevated levels of micro-nuclei and chromatin bridges seen in HUVECs grown 
on TiO2 raised serious concern for the potential future clinical application of this 
biomaterial. These genetic instability markers are a likely prerequisite to transformation 
of the cell into a tumour cell. The obvious effects of this could be catastrophic to the 
health of the individual. I decided that further research on this would be unjustified using 
the limited resources present in my current research post. To be able to take this 
material further would require specialist equipment able to modify the surface topology 
and chemistry of the TiO2, which is beyond the capability of my lab.  
       Although there is a deficit of novel bactericidal biomaterials for clinical applications, 
the use of this surface at this stage of development would be detrimental to the health of 
a patient, if said device is implanted. Further research needs to be conducted on the 
biochemical effect this surface has on physiological cells before clinical application can 
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be considered. This data, along with that of the immunofluorescence conducted within 
this research, would give researchers focussing on the development of these novel 
biomaterials an indication to the types of surface chemiphysical properties that should 
be avoided, or provide them with a basis for future surface developments. 
       Having optimised a cell culture protocol for HUVEC, I wanted to use this as a basis 
for generating a novel protocol for the culture of zebrafish ECs. Initially using Lonza 
EGM-2 media, I discovered that it is not a suitable culture medium for zebrafish larvae 
ECs to grow and replicate. Cell proliferation using this media was stunted and cell 
number declined after 24 h. Suggestions for further optimisation of this protocol would 
involve using FBS as a source of crude, undefined growth factors and other 
components necessary for cellular replication. Due to the variability and broad spectrum 
of its constituents, this media is a more versatile culture media relative to EGM-2, whose 
composition reflects the specific requirements of HUVEC. Further additions of growth 
supplements able to be recognised by zebrafish ECs may need to be added to the basal 
serum if the bovine versions do not allow for adequate cellular proliferation. 
Furthermore, during FACS, cells other than ECs may have been sorted, demonstrated 
as their cellular morphologies were dissimilar to that of ECs, and more characteristic of 
cells of the HPC lineage. This would have altered the outcome of the EC proliferation 
assay as cells other than ECs would have been counted. An additional variable affecting 
the reliability of the assay is the inclusion of dead and dying cells in the count. To evade 
these inappropriately high cellular counts, further rounds of EC validation are needed. 
Cellular markers specific for ECs need to be identified, such as VEGFR2, using 
immunofluorescence. In this way those cells that are successfully labelled with the 
antibodies will be counted. The application of a live/dead cell assay, using fluorophores 
that effectively stain live cells one colour and dead another, to the culture would allow 
for the exclusion of dead cells from the count.  
       Once the culture media has been optimised and a protocol to count only live ECs, 
the primary cells can be immortalised. hTERT is an enzyme that extends DNA 
telomeres thereby allowing a cell to replicate beyond the point of its Hayflick limit and 
potentially become immortal. Using hTERT that is compatible with zebrafish ECs, the 
primary cells have the capacity to become an immortal, non-transformed cell line. This 
will have application in future cell culture experiments that require a stable source of 
zebrafish ECs. These experiments are likely to gain in interest enormously to 
complement in vivo studies on zebrafish larvae. The data from which can be 




Culturing HUVEC with NHDF to generate blood vessels allowed me to understand the 
importance of cell-cell and cell-ECM interaction in the formation of vasculature. The 
addition of SW480 P and V tumour spheroids suggested a link between localised VEGF 
secretion and the upregulation of angiogenesis. This experiment also demonstrated how 
the incubatory period of the co-culture with each cell type depicts the resulting 
vasculature density. Work within this chapter has developed a protocol for this tumour 
angiogenesis assay, producing a blood vasculature density that would give quantifiable 
results regarding the angiogenic effect of VEGF. This provides the foundation for future 
opportunities in studying the effect of VEGF and other pro-angiogenic growth factors, as 
well as the effect of anti-angiogenic factors and drugs designed to inhibit the 
progression of vasculature expansion. Thus, this assay provides a screening assay for 
bioactive molecules and existing drugs which may have a second medical use. 
       Finally, work within this thesis attempted to develop a protocol for surface labelling 
HUVECs prior to proteomic analysis. Failure to separately label the apical and 
basolateral surfaces at 0°C with a biotinylating reagent demonstrated how difficult this 
is, even when the incubatory time of the HUVEC with the reagent was lowered to 5 min. 
From carrying out this experiment it is clear that basal surface labelling of HUVEC is 
more difficult than apical surface labelling, the majority of the label being trapped by the 
protein dense ECM and therefore not reaching the proteins on the basal surface of the 
cells. Additionally, there was a large amount of proteins being able to reach the basal 
surface of the HUVEC when the biotinylating reagent is added apically. Therefore, 
proteomic analysis wasn’t possible. Direct labelling of surface proteins with antibodies 
specific for proteins proven in HUVEC gave encouraging results. There is polarity of 
surface proteins seen in HUVEC, that of α5 integrin and ICAM-1 following the 
distribution pattern expected based on their physiological function. This validates this 
method of surface protein labelling and presents opportunities for future surface protein 
analysis.  
       Put together, the results from this project show promise for future research on ECs. 
Each chapter has set up opportunities for further cell culture assays with various 
applications. However, the work that I think shows the most potential going forward for 
further study is the development of a cell surface protein labelling technique. It is clear 
that labelling all the proteins on the apical and basal surfaces separately is very difficult, 
however directly labelling specific proteins of interest and imaging them using 
immunofluorescence presents a reliable method to gain data on their relative surface 
polarities. The integrity of blood vasculature is critical to their function. For the majority 
of the endothelium, having a continuous, fence-like sheet of ECs is essential for the 
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protection and homeostasis of the sub-endothelial tissue. These cells rely on 
specialised receptor molecules on their surfaces for transcytosis of molecules for 
cellular growth and proliferation. Little is known of the amount and identities of EC 
surface proteins at each cellular surface, and so little can be deduced of their function in 
this important physiological process. Unveiling the polarity of important surface proteins 
in HUVEC will provide crucial information on their functioning within ECs and hence will 
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